Rooted in Science. We put the health of your family first.

For nearly 25 years, ViaCord has been providing the highest quality, umbilical cord blood stem cell collections for families, and has been involved in cutting edge research to find new stem cell therapies for diseases like cancer, juvenile diabetes, and heart disease. Our mission is to provide the highest quality stem cell preservation service and care to our patients, families, and their physicians. We at ViaCord believe these words are much more than just a promise. They are the commitment we live by.

Cord blood stem cells are playing a major role in transplant medicine, an innovative therapeutic approach to treating disease. We've preserved the cord blood more than 350,000 newborns, and have released over 360 stem cell units for transplant or regenerative medicine research.

Our cord tissue processing method recovers substantially more cells than other banks. We recover cells from all 3 primary regions of the umbilical cord – to get your more cells 40 and offer families the potential for an increased number of cells for future treatments.

Genes can tell a lot about a person and detect certain diseases that might develop. Knowing a person’s unique genetic DNA blueprint can be a powerful tool for families to take a proactive approach to early detection, disease prevention and personalized medicine.

Whether it's testing newborns for life-threatening disorders, supporting scientists in finding better cures, or helping doctors treat disease, PerkinElmer's focus on human health extends beyond the lab and into hospitals and homes.

Contact Us

General: Hours of operation: 24 hours - 7 days a week

ViaCord | 930 Winter Street, Suite 2500   |   Waltham, MA 02451   |   Phone 1-866-668-4895 | Outside U.S.:1-781-663-5800  | Email:  info@viacord.com   | Fax: 1-866-565-2243

Finance Department:Hours of operation: 9:00am - 6:00pm EST 

Attn: ViaCord Finance   ViaCord 930 Winter Street, Suite 2500  |  Waltham, MA 02451  |  Phone 1-800-991-2483 | Outside U.S.:1-781-663-6235  | Email:  viacord.finance@perkinelmer.com   

ViaCord Press Releases

Click below to view our press releases regarding research, innovations in newborn stem cell science and treatments and important announcements:

View Press Releases

  1. Phase II Clinical Trial Data Establishes Effectiveness of using a Child’s Own Cord Blood to Treat Cerebral Palsy

    Key Discoveries in the Therapeutic Application of Cord Blood: Improvement of Motor Function in Children with Cerebral Palsy

    WALTHAM, Massachusetts – October 31, 2017Research published in Stem Cells Translational Medicine shows encouraging developments related to using a child’s own cord blood to treat childhood brain injury known as cerebral palsy (CP). 

    The research from a Phase II clinical trial indicates that patients with CP who were treated with an infusion of an adequate dose of their own cord blood, which had been collected and stored at birth, saw a significant improvement in their motor function. Of the 63 children receiving treatment, those who were given a dose higher than 20 million cells per kilogram showed improvements in motor function measured on a validated scale for assessing motor function in children with CP called the Gross Motor Function Measure (GMFM-66).

    “This is the first demonstration of a therapy producing durable improvements in motor function in young children with CP. We are very encouraged by these results. Our research has indicated that autologous cord blood infusions are feasible, safe and easily administered in the outpatient setting,” said Joanne Kurtzberg, MD, Director, Carolinas Cord Blood Bank and Pediatric Blood and Marrow Transplant Program; Chief Scientific Officer, Robertson Clinical and Translational Cell Therapy Program, Duke University, who led the clinical trial. 

    The purpose of this Phase II trial was to determine the efficacy of using a child’s own (autologous) cord blood for the treatment of pediatric patients with cerebral palsy. The primary measure of efficacy was a significant change in standardized measure of motor function over what would have been expected at one year without the treatment. Further details can be found here.

    “Before our son Patrick’s cord blood treatment, things were so overwhelming for him and our family. Patrick struggled with therapy, school and the normal daily activities you take for granted,” said GiGi and Kevin Rooney, the parents of a child who participated in the study. “Today, after his cord blood treatment, Patrick has great stamina and endurance and the confidence to try new things. Having his cord blood and being in this study has tremendously impacted our lives for the better and we are truly grateful.” 

    These findings in children with CP follow the publication in April 2017 of results from a Phase I trial testing the safety of using a child’s own cord blood to treat Autism Spectrum Disorder (ASD) published in Stem Cells Translational Medicine. Duke continues to study the use of cord blood to treat children with Autism Spectrum Disorder in a Phase II Clinical Trial using both autologous and allogeneic cord blood, and recently completed a Phase I study in children with CP who were treated with cord blood from a sibling. 

    “For more than 20 years, ViaCord has collaborated on projects to determine the clinical utility of cord blood stem cells. These initial findings mark an exciting development in the potential use of cord blood stem cells for treating Cerebral Palsy, and a significant step in establishing the role of cord blood beyond transplant medicine and into regenerative medicine, including Autism,” said Morey Kraus, Chief Scientific Officer, ViaCord. “We are proud that ViaCord families were able to participate in this historic study by having access to their own cord blood, and we look forward to helping many more families.” 

    ViaCord, PerkinElmer’s (NYSE:PKI) cord blood and cord tissue preservation business, has preserved the umbilical cord stem cells of more than 350,000 newborns and released over 350 cord blood units for treatment and clinical research studies. It has released more than 200 cord blood units for use in the treatment of nearly 80 diseases including acute lymphoblastic leukemia and sickle cell disease and more than 150 cord blood units for use in clinical research studies including this study for Cerebral Palsy and Autism Spectrum Disorder. 

    Please visit www.viacord.com for more information. Follow ViaCord on Twitter @ViaCord

    About PerkinElmer 

    PerkinElmer is a global leader committed to innovating for a healthier world. Our dedicated team of 9,000 employees worldwide are passionate about providing customers with an unmatched experience as they help solve critical issues especially impacting the diagnostics, discovery and analytical solutions markets. Our innovative detection, imaging, informatics and service capabilities, combined with deep market knowledge and expertise, help customers gain earlier and more accurate insights to improve lives and the world around us. The Company reported revenue of approximately $2.1 billion in 2016, serves customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com

    ### 

    Contact:
    Elizabeth Tripp
    etripp@apcoworldwide.com
    646-556-9324

  2. PerkinElmer Extends Clinical Whole Genome Sequencing Services

    FOR IMMEDIATE RELEASE
    September 7, 2017

    WALTHAM, Massachusetts – September 7, 2017 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, expanded its Whole Genome Sequencing (WGS) services to families that preserve  their cord blood and cord tissue with ViaCord.   This launch follows the Company’s recent introduction of its clinical WGS services

    Parents that choose ViaCord, PerkinElmer’s cord blood and cord tissue preservation business, now have the opportunity to benefit from a physician-ordered WGS test of their child’s DNA via a simple saliva test. The test examines a broad range of disease-related genes and provides diagnostic findings contributing to pediatric onset diseases. Additionally, the test reports on pharmacogenetic variants used to optimize certain drug selection. 

    “WGS is another great opportunity for families to identify and prepare for important health concerns, positioning themselves to benefit from the fast moving area of personalized medicine,” said Morey Kraus, chief scientific officer, ViaCord. “We have seen tremendous progress using cord blood stem cells to treat disease, and I expect families who make such health conscious decisions to benefit from WGS as well.  Additionally, with the rapid progress we’ve seen with regenerative medicine and gene editing, insights from WGS may be used in the future, in combination with a family’s cord blood and cord tissue, to optimize the design of a treatment plan.  This is a very exciting next new step in advancing personalized medicine.”

    ViaCord has preserved the umbilical cord stem cells of more than 350,000 newborns and released over 360 cord blood units for treatment and clinical research studies.  It has released more than 200 cord blood units for use in the treatment of nearly 80 diseases including acute lymphoblastic leukemia and sickle cell disease and more than 150 cord blood units for use in clinical research studies including for Cerebral Palsy and Autism Spectrum Disorder.

    About PerkinElmer
    PerkinElmer, Inc. is a global leader committed to innovating for a healthier world. Our dedicated team of 9,000 employees worldwide is passionate about providing customers with an unmatched experience as they help solve critical issues especially impacting the diagnostics, discovery and analytical solutions markets. Our innovative detection, imaging, informatics and service capabilities, combined with deep market knowledge and expertise, help customers gain earlier and more accurate insights to improve lives and the world around us.   The Company reported revenue of approximately $2.1 billion in 2016, serves customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

    Factors Affecting Future Performance
    This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) our ability to obtain future financing; (19) restrictions in our credit agreements; (20) the approval of the Brexit Referendum in the United Kingdom; (21) our ability to realize the full value of our intangible assets; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption "Risk Factors" in  our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.


    Media Contact:
    Brian Willinsky
    +1-781-663-5728
    brian.willinsky@perkinelmer.com

  3. Phase I Clinical Trial Examines Safety of Using Cord Blood Stem Cells for Treating Children with Autism Spectrum Disorder

    FOR IMMEDIATE RELEASE
    April 5, 2017

    WALTHAM, Mass. – April 5, 2017–  Novel research results from Duke University’s Robertson Clinical and Translational Cell Therapy Program published today in the April issue of Stem Cells Translational Medicine indicate promising developments related to using a baby’s own cord blood stem cells to treat Autism Spectrum Disorder (ASD).

    Drs. Joanne Kurtzberg, MD, Director, Carolinas Cord Blood Bank and Pediatric Blood and Marrow Transplant Program; Chief Scientific Officer, Robertson Clinical and Translational Cell Therapy Program and Geraldine Dawson, PhD, Professor of Psychiatry and Behavioral Sciences; Professor of Pediatrics and Psychology and Neuroscience; Director, Duke Center for Autism and Brain Development, led the Phase 1 clinical trial. ViaCord, PerkinElmer’s private cord blood and cord tissue preservation business, helped to fund the study and provided nearly one-half of the cord blood units used by the participating families. 

    “We are pleased that this study demonstrated the safety of treating children with ASD with their own cord blood,” said Kurtzberg.  “We’re also encouraged that, while small and non-randomized, there were observed improvements in a majority of the children reported by clinicians and parents.  Without the support of ViaCord and later, the Marcus Foundation, the study would not have been possible.  We are now hoping to replicate these preliminary results in a Phase II randomized clinical trial for which enrollment is nearly complete.”

    The trial was designed to determine the safety of an intravenous infusion of autologous umbilical cord blood for the treatment of pediatric patients with ASD.  A secondary research endpoint to evaluate the feasibility of outcome measures was based on the change in each child’s socialization and communication abilities and autism symptoms, measured via parent report, direct observation, and clinician judgment. The study also incorporated novel methodologies using eye-tracking that assessed how the child processed social information.  The results indicated that the treatment is safe and preliminarily indicated improvements in symptoms across all domains in the majority of children receiving an adequate cell dose.

    “When my son was just a year old, he was overly sensitive to noises like lawn mowers and was not babbling at all,” said Kristina, a mother whose child participated in the study. “But since his treatment at age 3, and in conjunction with therapy, his improvement has been steady and he’s now very social and able to interact independently with his peers, he can communicate more clearly with children and adults, and his sensory problems are gone. With support, he entered a mainstream elementary school program this past fall. We are extremely grateful to have participated in this study, and so happy with his continued improvement, now years after his treatment.”

    “For more than 20 years, ViaCord has actively participated in developments to increase the clinical utility of cord blood stem cells.  Over the last few years, cord blood applications have expanded beyond transplant medicine into areas of regenerative medicine like ASD and brain injuries,” said Morey Kraus, Chief Scientific Officer, ViaCord. “I’ve never been more optimistic about the potential of cord blood. It is very gratifying to have collaboration with Drs. Kurtzberg and Dawson at Duke in this ground breaking trial having the potential to transform the lives of thousands of families who have children with ASD.”

    Further details on the Phase II trial can be found at:  clinicaltrials.gov/ct2/results?term=NCT02847182

    ViaCord has preserved the umbilical cord stem cells of more than 350,000 newborns and released stem cells for the treatment of diseases such as acute lymphoblastic leukemia, thalassemia major, and sickle cell disease. It has also released more than 340 units of cord blood for clinical use, including this ASD study. For over 25 years, cord blood stem cells have been used in transplant medicine and today can be used in the treatment of nearly 80 diseases.  Please visit www.viacord.com for more information. Follow ViaCord on Twitter @ViaCord.


    About PerkinElmer

    PerkinElmer, Inc., a global leader focused on innovating for a healthier world, provides private cord blood and cord tissue preservation to families through ViaCord, LLC.  PerkinElmer reported revenue of approximately $2.1 billion in 2016, has about 9,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

     ###

    Contact:

    Elizabeth Tripp
    etripp@apcoworldwide.com
    646-556-9324

  4. ViaCord Launches Phase I Clinical Trial with Leading Academic Medical Center to Study Impact of Cord Blood Infusion in Children with Autism

    FOR IMMEDIATE RELEASE
    June 16, 2014  


    Breakthrough Research to Investigate Safety of Cord Blood Stem Cells as Potential Future Treatment Option for Autism Spectrum Disorder

    WHAT:  ViaCord, PerkinElmer's family cord blood and tissue preservation business, announced the launch of a phase I clinical trial at Duke University Medical Center to investigate the safety of autologous umbilical cord blood infusion in children with Autism Spectrum Disorder (ASD).

    According to a recent report1 by the Centers for Disease Control and Prevention (CDC), the number of U.S. children with ASD has sharply increased to 1 in 68 -- a 30 percent increase from two years ago, when the CDC estimated that 1 in 88 children had this disorder.

    "We are pleased to collaborate with Duke University Medical Center by sponsoring this important study to determine the safety of cord blood for potentially treating this prevalent disorder facing children worldwide," said Morey Kraus, Chief Scientific Officer, ViaCord. "Cord blood has not traditionally been closely evaluated as a possible safe treatment option for ASD. Aligning our efforts with the experts at a leading medical research center underscores our commitment to improving the lives of children and families struggling with ASD."

    HOW: The single site Phase 1 safety study includes 20 subjects and is designed to objectively evaluate safety and multiple measures of social behavior and irritability in young children diagnosed with ASD. Children ages 24-72 months of age with a confirmed diagnosis of ASD and a banked autologous unit of umbilical cord blood of adequate size and quality may be eligible to participate.

    Researchers will assess the feasibility of various outcome measures to determine which measure(s) can be used as primary and secondary endpoints for a future randomized phase II clinical trial.

    "We are excited to conduct this important study in children with Autism Spectrum Disorder. We hope to learn whether cord blood infusions are safe and to define the best tests to use to study the effects of cord blood in future studies", said Joanne Kurtzberg, MD, Director, Carolinas Cord Blood Bank and Pediatric Blood and Marrow Transplant Program, Chief Scientific Officer, Robertson Clinical and Translational Cell Therapy Program, Duke University.

    MORE: More information on the Autism clinical trial at Duke University Medical Center is available by contacting cordbloodtherapyinfo@dm.duke.edu or 844-800-2673.

    Cord blood is also being used in the Duke Translational Medicine Institute's Cerebral Palsy clinical trial, which has recently completed enrollment. Duke's researchers have accepted numerous cord blood units from ViaCord for this study, which investigates the potential benefits of autologous reinfusion of cord blood stem cells for children with cerebral palsy.

    Cord blood stem cells have been used in the treatment of nearly 80 diseases, and more than 30,000 treatments using donor cord blood have been conducted worldwide using cord blood stem cells. ViaCord has released stem cells for the treatment of diseases ranging from acute lymphoblastic leukemia, thalassemia major and sickle cell disease. ViaCord has preserved the umbilical cord stem cells of more than 300,000 newborns.

    ViaCord's family cord blood and cord tissue services also offer expectant families the opportunity to bank their baby's umbilical cord blood and tissue for potential medical use by the child or a related family member. Through its Sibling Connection Program, ViaCord also provides the opportunity for expectant parents, who have an eligible child in need of a transplant, to receive cord blood and cord tissue stem collection, processing and five years of storage, at no cost. Please visit www.viacord.com for more information.

    About PerkinElmer, Inc.

    PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2.2 billion in 2013, has about 7,600 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.


    REFERENCES 
     
     
     
     
    Media Contact:
    ViaCord
    Caroline Starke
    646-218-8747
  5. Cord Blood Registry & ViaCord Praise Introduction of Family Cord Blood Banking Act

    FOR IMMEDIATE RELEASE
    December 16, 2013

     
     

    Cord Blood Registry & ViaCord Praise Introduction of Family Cord Blood Banking Act

    Cord Blood Registry (CBR) and ViaCord, a division of PerkinElmer Inc. - two of the largest family cord blood banks in the nation - joined together today to praise U.S. Representatives Aaron Schock (R-IL) and Ron Kind (D-WI) for reintroducing HR 3673, the Family Cord Blood Banking Act.

    The bipartisan legislation will ensure that umbilical cord blood banking services are recognized as a qualified medical expense so that the more than one million American families who have already banked their child's umbilical cord blood stem cells, and the millions of families who choose to do so in the future, can use tax-advantaged health dollars for the collection, processing and storage of these life-saving cells.

    "As industry leaders, both CBR and Viacord are committed to doing all we can to increase awareness of the power of newborn stem cells to improve lives today and their potential to revolutionize treatment for many conditions in the future. We wholly endorse the Family Cord Blood Banking Act to establish cord blood banking as a qualified medical expense, thus helping American families access cord blood banking services through tax-advantaged health accounts," said Geoff Crouse, CEO of CBR.

    Umbilical cord blood contains unique stem cells that can be collected immediately following birth from the umbilical cord. These stem cells have been used in more than 30,000 transplants worldwide during the last 25 years in the treatment of nearly 80 diseases in both adults and children. These stem cells also show great promise for regenerative medicine applications; in fact, aside from current treatments for many anemias, leukemia and certain other cancers, FDA-regulated clinical trials are currently underway to study the use of a child's own cord blood stem cells to treat autism, cerebral palsy, traumatic brain injury and pediatric stroke.

    "Viacord is excited to join with CBR in supporting this important piece of legislation. The Family Cord Blood Banking Act will make cord blood banking more affordable for American families and provide incentives to ensure that this valuable health resource is never thrown away," said Jim Corbett, President of Diagnostics for PerkinElmer.        

    Specifically, the Family Cord Blood Banking Act will allow expectant parents to use tax-free dollars to pay for cord blood banking services through Health Savings Accounts (HSA), Health Reimbursement Accounts (HRA), Flex Spending Accounts (FSA) and the medical expenses tax deduction. Unlike other medical therapies that can be acquired at any time, the very nature of cord blood requires that it be processed and stored before medical use. Consequently, cord blood banking is a medical expense even though the use of these cells may not occur until later. Finally, the Family Cord Blood Banking Act will allow more Americans to recognize the long-term healthcare benefits of having a source of their own genetically unique stem cells stored for future use. 


    About Cord Blood Registry

    Cord Blood Registry® (CBR®) is the world's largest newborn stem cell company.  Founded in 1992, CBR is entrusted by parents with storing more than 500,000 cord blood and cord tissue units. The company is pioneering FDA-regulated clinical trials through partnerships with leading medical institutions exploring the use of newborn stem cells to treat a variety of serious conditions such as autism, cerebral palsy and traumatic brain injury. For more information, visit www.cordblood.com.


    About PerkinElmer, Inc.
    PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $2.1 billion in 2012, has about 7,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com. Join the conversation and follow us on twitter at www.twitter.com/perkinelmernews.


    # # #

    Contacts:


    Cord Blood Registry

    Brian Plummer

    650-635-1420 ext. 255               

    bplummer@cordblood.com


    Edelman (On behalf of PerkinElmer, Inc.)

    Jen Reid 

    404-460-8587 

    jen.reid@edelman.com


    SOURCE Cord Blood Registry and Viacord

  6. PerkinElmer Completes Acquisition of ViaCell

    FOR IMMEDIATE RELEASE

    11/15/07


    PerkinElmer Completes Acquisition of ViaCell


    Strengthens Commitment to Neonatal, Prenatal and Maternal Health Solutions


    WALTHAM, Mass. – PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences, today announced that it has successfully completed its acquisition of ViaCell, Inc., a biotechnology company specializing in the collection and preservation of umbilical cord blood stem cells. The acquisition expands PerkinElmer’s offerings and reach in the neonatal, prenatal and maternal health markets.


    ViaCell’s ViaCord® product offering allows expectant families to preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 life-threatening diseases, including certain leukemias, immune system deficiencies, and metabolic disorders. The addition of ViaCord and ViaCell’s highly qualified sales and marketing organization provides PerkinElmer with a leading offering in the rapidly growing cord blood banking business, as well as an enhanced ability to reach obstetric professionals and prospective parents. ViaCell customers will continue to benefit from ViaCord’s high-quality cord blood banking offering and expertise, and now will have access to a wider range of neonatal, prenatal and maternal health solutions from PerkinElmer.


    “PerkinElmer is committed to protecting the health of mothers and babies from pregnancy through birth and beyond,” said Robert F. Friel, President and Chief Operating Officer, PerkinElmer. “The addition of ViaCell marks another step in our efforts to become a leading provider of innovative prenatal, neonatal and maternal healthcare solutions. We will continue to look for opportunities to build our product portfolio and provide the most comprehensive and accurate assessment of newborn and maternal health to families and their healthcare providers.”


    PerkinElmer is the world’s leading provider of newborn screening systems, offering the world’s first and only tandem mass spectrometry (MS/MS) kit cleared by the FDA as an aid to screening for inborn errors of metabolism. The Company continues to drive the advancement of newborn screening with the capability to analyze more than 40 disease markers with a single blood sample. PerkinElmer estimates that every baby screened in the U.S. today is tested using its screening tools, and has helped identify more than 100,000 infants globally who were determined to be at risk for potentially life-threatening diseases.


    As part of its rapidly growing offerings for prenatal and maternal health, PerkinElmer currently offers Ultra-Screen®, a first-trimester prenatal screening protocol designed to provide patient-specific risk assessment for certain chromosomal abnormalities, through its clinical test subsidiary, NTD Laboratories. The Company also holds a global licensing agreement to develop assay kits for the ADAM12 biochemical marker, which has broad potential in maternal health screening for fetal chromosomal abnormalities, and has secured global rights for Placental Protein 13 (PP13), a new maternal serum marker currently under investigation that has shown potential for early detection of pre-eclampsia in low-risk groups.


    Factors Affecting Future Performance

    This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to our genetic screening business. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.


    PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.55 billion in 2006, has 8,500 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE. 


    # # #


    For further information regarding PerkinElmer, please contact:


    Investor Relations:

    Michael A. Lawless 
    PerkinElmer, Inc. 
    (781) 663-565


    Media Contact:

    Michael J. Lorenc

    PerkinElmer, Inc.

    (781) 663-5701


    PerkinElmer, Inc.

    940 Winter Street

    Waltham, MA 02451 USA

    Phone: 781-663-6900

    Fax: 781-663-5985

    www.perkinelmer.com

     

  7. PerkinElmer ViaCord Research Institute™ and M.D. Anderson Cancer Center extend collaboration to study cord blood stem cell expansion system in adult transplantation.

    FOR IMMEDIATE RELEASE
    1/16/09
    • Study Seeks to Discover Method of Treating More Adults Using Cord Blood Stem Cells
    • M. D. Anderson Clinical Research Trial Explores Co-Culture Expansion Technology
     
    WALTHAM, MASSPerkinElmer, Inc., a global leader focused on the health and safety of people and their environment, today announced the extension of a research collaboration between its ViaCord Research Institute™ (VRI™) and The University of Texas M.D. Anderson Cancer Center. The collaboration underscores VRI’s commitment to advancing technologies that multiply cord blood stem cells, with the goal of treating more diseases and more adults.
     
    M. D. Anderson is conducting a clinical trial to explore a cord blood expansion technology called “Co-culture.” Cord blood is a valuable, non-controversial source of stem cells with proven effect in treating more than 70 serious diseases, including many cancers. However, today, the quantity of stem cells available in a single umbilical cord blood unit is often not sufficient to treat adult patients. Cord blood expansion technologies, such as Co-culture, may make it possible to use these stem cells to treat even more patients by increasing the total number of stem cells available from a single cord blood unit.
     
    The trial is being led by Elizabeth J. Shpall, MD, professor of stem cell transplantation and medical director of the Stem Cell Transplantation and Cellular Therapy Center at M.D. Anderson. The trial seeks to determine whether the use of “Co-culture” will be safe and result in more rapid engraftment in adults receiving cord blood transplants.
     
    “We are honored to partner with M. D. Anderson on this important initiative,” said Morey Kraus, chairman, Medical Scientific Advisory Board, ViaCord Research Institute. “The collective goal of VRI’s research initiatives is to expand the current uses of cord blood stem cells so they may treat more patients and more diseases in the future. The research being conducted by Dr. Shpall is key to unlocking the full therapeutic promise of umbilical cord stem cells by increasing the total number of cells available from a single cord blood unit.”
     
    Based on the results of this trial, ViaCord, PerkinElmer’s cord blood banking business, and M.D. Anderson will determine the feasibility of using Unrestricted Somatic Stem Cells (USSCs) derived from cord blood in the Co-culture of cord blood units for transplantation. USSCs, proprietary to ViaCord (patent pending #09/985,335), are a type of stem cell found in umbilical cord blood, which have the ability to differentiate into many cell types, including endothelial cells, fat, bone, cartilage and neuronal cells.
     
    About M. D. Anderson
     
    The University of Texas M. D. Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. M. D. Anderson is one of only 39 Comprehensive Cancer Centers designated by the National Cancer Institute. For four of the past five years, M. D. Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in U.S. News and World Report. For more information, visit www.mdanderson.org.
     
    About PerkinElmer, Inc.
     
    PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and their environment. The Company reported revenue of $1.8 billion in 2007, has approximately 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
     
    About the ViaCord Research Institute
     
    The ViaCord Research Institute (VRI) is dedicated to developing and supporting science, technology and medical treatments using cord blood stem cells while leveraging comprehensive genetic information to facilitate the best treatment options for families. Led by a team of leading scientists and physicians, the ViaCord Research Institute’s efforts are focused on investigating new potential future uses of umbilical cord blood-derived stem cells in five key areas: cord blood technologies, emerging stem cell therapies, genetic screening, product development and related transplants. For more info, visit www.viacord.com
     
    ###
     
    Media Contact:
     
    For PerkinElmer, Inc.
     
    David Blackett, PerkinElmer, Inc.
     
  8. PerkinElmer ViaCord Research Institute™ to support diabetes research effort at University of Massachusetts Medical School

    FOR IMMEDIATE RELEASE
    1/22/09
    PerkinElmer ViaCord Research Institute™ to support diabetes research effort at University of Massachusetts Medical School
     
     
    ■UMMS Study Exploring Potential Use of Umbilical Cord Blood-Derived Stem Cells in Treating Type 1 Diabetes 
     
     
    ■Agreement Furthers VRI™ Commitment to Expanding Medical Uses of Cord Blood 
     
     
    WALTHAM, MASS – PerkinElmer, Inc., a global leader focused on the health and safety of people and their environment, today announced that its ViaCord Research Institute™ (VRI™), which focuses on supporting science, technology and medical treatments using cord blood stem cells, will support the University of Massachusetts Medical School (UMMS) in its research efforts into the potential use of umbilical cord blood-derived stem cells in treating type 1 diabetes. The initiative will be led by chief investigator Dale L. Greiner, Ph.D., of UMMS’ Diabetes and Endocrinology Research Center. 
     
     
    “We are very pleased to support UMMS’ continued efforts to find a cure for Type 1 diabetes,” said Morey Kraus, chairman, Medical Scientific Advisory Board, ViaCord Research Institute. “Cord blood is a valuable, non-controversial source of stem cells with proven effect in treating more than 70 serious diseases and we believe exploring this potential in the treatment of Type 1 diabetes and other immune disorders is critical. VRI is committed to supporting important research, like that being conducted by Dr. Greiner, to help expand the medical use of cord blood derived stem cells to include the treatment of additional diseases, including diabetes.”
     
     
    “Our primary goal is to study the ability of these cord blood derived cells to modulate a human immune system in a pre-clinical animal model,” said Dale L. Greiner, Ph.D., professor of medicine, University of Massachusetts Mass Medical School. “This collaboration between ViaCord and the University of Massachusetts Medical School is a great opportunity for interaction of the biomedical research expertise at the university with a global technology company dedicated human health to fulfill the goals of bringing cutting edge research in the state to the public.”
     
     
    According to the American Diabetes Association, diabetes is the fifth leading cause of death in the United States. Diabetes affects more than 23.6 million Americans, or 7.8 percent of the population, and is estimated to have a total annual economic cost of $174 billion. Type 1 diabetes, which accounts for between five and ten percent of all diagnosed cases of diabetes, is an autoimmune disease, generally occurring in children and young adults. Because patients with type 1 diabetes do not product insulin naturally, they must have insulin delivered by injection or a pump to help maintain their health. There is no known way to prevent type 1 diabetes.
     
     
    About the University of Massachusetts Medical School
    The University of Massachusetts Medical School, one of the fastest growing academic health centers in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than $193 million in research funding annually, 80 percent of which comes from federal funding sources. The work of UMMS researcher Craig Mello, PhD, an investigator of the prestigious Howard Hughes Medical Institute (HHMI), and his colleague Andrew Fire, PhD, then of the Carnegie Institution of Washington, toward the discovery of RNA interference was awarded the 2006 Nobel Prize in Physiology or Medicine and has spawned a new and promising field of research, the global impact of which may prove astounding. UMMS is the academic partner of UMass Memorial Health Care, the largest health care provider in Central Massachusetts. For more information, visit www.umassmed.edu.
     
     
    About PerkinElmer, Inc.
     
    PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and their environment. The Company reported revenue of $1.8 billion in 2007, has approximately 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE. 
     
     
    About the ViaCord Research Institute
     
    The ViaCord Research Institute (VRI) is dedicated to developing and supporting science, technology and medical treatments using cord blood stem cells while leveraging comprehensive genetic information to facilitate the best treatment options for families. Led by a team of leading scientists and physicians, the ViaCord Research Institute’s efforts are focused on investigating new potential future uses of umbilical cord blood-derived stem cells in five key areas: cord blood technologies, emerging stem cell therapies, genetic screening, product development and related transplants. For more info, visit www.viacord.com
     
     
    Factors Affecting Future Performance
     
    This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) markets into which we sell our products decline or do not grow as anticipated; (4) our failure to adequately protect our intellectual property; (5) the loss of any of our licenses or licensed rights; (6) our ability to compete effectively; (7) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (8) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (9) disruptions in the supply of raw materials and supplies; (10) our ability to produce an adequate quantity of products to meet our customers' demands; (11) the manufacture and sale of products may expose us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with health care industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) restrictions in our credit agreements; (18) our ability to realize the full value of our intangible assets; and (19) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. 
     
     
     
     
    ###
     
    Media Contact:
     
    For PerkinElmer, Inc.
     
    David Blackett, PerkinElmer, Inc.
     
    Email: david.blackett@perkinelmer.com 
  9. PerkinElmer's ViaCord Releases 200th Umbilical Cord Blood Unit for Stem Cell Treatment

    CAMBRIDGE, MAPerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced that its family cord blood banking business, ViaCord, has released its 200th umbilical cord blood stem cell unit for treatment purposes. The 200th unit will be used in a clinical trial intended to treat cerebral palsy with a re-infusion of a child’s own umbilical cord stem cells. 
     
    Twenty years ago, cord blood stem cells were used to treat just one disease, Fanconi’s anemia, but today there are nearly 80 diseases treatable with cord blood stem cells, including cancers, certain blood disorders and immunodeficiencies. Cord blood stem cells are also being studied by scientists in regenerative medicine trials for the treatment of cerebral palsy and type 1 diabetes. Regenerative medicine applications require a patient to use their own cord blood stem cells for treatment. 
     
    Morey Kraus, Chief Scientific Officer, Specialty Diagnostics, PerkinElmer, said, “This milestone provides an opportunity to think about the future potential of cord blood stem cells. A growing number of families are preserving their baby’s cord blood for its potential value in treating debilitating indications where there may otherwise be limited options.” 
     
    At the 2010 Cord Blood Transplantation Symposium, ViaCord presented its data demonstrating survival rates from transplants in hematopoietic transplants using ViaCord units. The study looked at children affected by malignant and non-malignant hematological disorders and showed an overall survival rate of 87 percent at one year in children after transplantation. At eight years, the survival rate was 84 percent. 
     
    This is the first time eight-year data was published by a family cord blood bank, and these survival rates represent the highest published survival rates in family banking. The results show that the cord blood collected and processed by ViaCord met or exceeded expectations regarding their clinical utility and confirm the importance of cord blood banking. 
     
    Dr. Mahendra Patel, MD, pediatric hematologist/oncologist in San Antonio, Texas, said, “Cord blood banking is critical to society as a whole given cord blood stem cells’ multiple medical uses. Companies such as ViaCord provide families with access to stem cells at a time when other medical options are limited or non-existent. ViaCord is a leader in bringing this valuable resource for families to the forefront of public awareness.” 
     
    ViaCord intends to continue publishing its updated post-transplant survival rates and provide excellence in family cord blood banking services. ViaCord will also continue to raise awareness about the importance of cord blood banking in the hopes of giving more families access to cord blood stem cells for current and future potential treatments. 
     
    ViaCord allows expectant families the opportunity to preserve their baby’s umbilical cord blood for potential medical use by the child or a related family member. To date, ViaCord has preserved over 230,000 newborns’ umbilical cord blood. 
     
     
    About PerkinElmer, Inc. 
     
    PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company has approximately 6,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or at 1-877-PKI-NYSE. 
     
    # # #
     
    Media Contact: 
     
    Amanda Connolly 
    Edelman (on behalf of PerkinElmer, Inc.) 
    Phone: 404-832-6785 
  10. PerkinElmer’s ViaCord Teams up with Mia Hamm to Promote Cord Blood Education and Assist Transplant Families

    FOR IMMEDIATE RELEASE
    8/11/08
     
    PerkinElmer’s ViaCord Teams up with Mia Hamm to Promote Cord Blood Education and Assist Transplant Families
     
    Embarks on Joint Public Awareness Campaign, Provides Financial Support to Mia Hamm Foundation
     
    CAMBRIDGE, Mass.--(BUSINESS WIRE)--ViaCord, a wholly-owned subsidiary of PerkinElmer, Inc. (NYSE: PKI), today announced a new partnership with global sports superstar Mia Hamm and the Mia Hamm Foundation to jointly raise awareness of the value and benefits of umbilical cord blood banking, and support the Foundation’s mission of supporting cord blood or bone marrow transplant patients and their families.
     
    Through this agreement, the Company will provide funding to the Mia Hamm Foundation, and both parties will work together on a broader national campaign focused on education and awareness of critical issues surrounding the benefits of cord blood banking and transplants.
     
    When her twins were born in 2007, Hamm and her husband made the decision to save their cord blood with ViaCord. Cord blood is a valuable, non-controversial source of stem cells with proven effect in treating more than 70 serious diseases, including many cancers and immunodeficiencies. To date, more than 10,000 cord blood transplants have been performed worldwide. Recently, the use of autologous (one’s own) cord blood has emerged as a potential treatment option for diabetes and cerebral palsy. In the future, medical use of cord blood stem cells may be expanded to include the treatment of cardiac disease or stroke.
     
    “Mia Hamm is one of the world’s premier athletes, who exhibits class and grace both on and off the field. She shares our excitement about the benefits and potential of cord blood stem cells, and we are truly excited about the opportunity to work together,” said Jim Corbett, president, ViaCord. “Our scientific know-how and cord blood banking expertise coupled with Mia’s passion for this subject provides a winning combination in driving greater awareness of the benefits and possibilities of using cord blood stem cells.”
     
    “I lost my brother Garrett to Aplastic Anemia, one of the diseases cord blood can treat, so my family knows first hand the value of having access to a matching cord blood unit,” said Hamm. “I am thrilled to team with ViaCord to help educate expecting families on the value of cord blood banking, while also increasing my Foundation’s ability to assist more families in need of a cord blood or bone marrow transplant.”
     
    PerkinElmer is the established global leader in neonatal screening and is committed to growing its offerings in prenatal screening and maternal health worldwide. The Company provides customers with the most comprehensive array of newborn screening solutions available, including the world’s first and only tandem mass spectrometry kit cleared by the FDA, and PerkinElmer Genetics, a full-service newborn screening laboratory. PerkinElmer provides families the option of preserving their baby’s umbilical cord blood at the time of birth for possible future medical use in treating more than 70 diseases, many cancers and immunodeficiencies through its ViaCord business. PerkinElmer also provides first-trimester prenatal risk assessment testing under the brand name Ultra-Screen, through its NTD Laboratories subsidiary.
     
    PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.8 billion in 2007, has 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
     
    About the Mia Hamm Foundation
     
    The Mia Hamm Foundation is a non-profit, national organization dedicated to raising funds and awareness for families in need of a bone marrow or cord blood transplant patients and the development of more opportunities for young women to participate in sport. For more information, please visit http://www.miafoundation.org.
     
     
     
     
     
    Contacts
     
    PerkinElmer, Inc.
    Investor Relations:
    Michael A. Lawless, 781-663-5659
    or
    Media Contact:
    Stephanie R. Wasco, 781-663-5701
  11. PERKINELMER ANNOUNCES SUCCESSFUL COMPLETION OF CASH TENDER OFFER FOR VIACELL

    FOR IMMEDIATE RELEASE
    11/9/07
     
    PERKINELMER ANNOUNCES SUCCESSFUL COMPLETION OF CASH TENDER OFFER FOR VIACELL
     
     
    Waltham and Cambridge, MA (November 9, 2007)PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences, today announced the successful completion of its tender offer to acquire all outstanding shares of common stock of ViaCell, Inc. (Nasdaq: VIAC), at a price of $7.25 per share, in cash.
     
    The initial offering period for the tender offer expired at 12:00 midnight, New York City time, at the end of Thursday, November 8, 2007, with approximately 37.9 million shares of ViaCell common stock being tendered, including approximately 6.8 million shares tendered under guaranteed delivery procedures, for $7.25 per share. All shares that were validly tendered and not withdrawn have been accepted for purchase. The shares tendered and accepted for purchase represent more than 90% of the outstanding shares of ViaCell common stock.
     
    Merger
     
    PerkinElmer intends to promptly acquire all of the remaining ViaCell shares by means of a short-form merger under Delaware law at the same price per share paid in the tender offer. Upon completion of the merger, ViaCell will become an indirect wholly owned subsidiary of PerkinElmer, Inc.
     
    Cautionary Note Regarding Forward-Looking Statements
     
    Statements in this press release regarding the proposed transaction between PerkinElmer and ViaCell, the expected timetable for completing the proposed transaction, and any other statements about PerkinElmer or ViaCell managements’ future expectations, beliefs, goals, plans or prospects constitute forward-looking statements. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the possibility that certain closing conditions to the transaction will not be met, the ability to consummate the transaction, the ability of PerkinElmer to successfully integrate ViaCell’s operations and employees; the ability to realize anticipated synergies and cost savings; and the other factors described in PerkinElmer’s Annual Report on Form 10-K for the year ended December 31, 2006, and in ViaCell’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, each of which has been filed with the SEC. Except as otherwise required by law, PerkinElmer and ViaCell disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
     
    About PerkinElmer
     
    PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. PerkinElmer, Inc. reported revenues of $1.55 billion in 2006, has 8,500 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
     
    About ViaCell
     
    ViaCell, Inc. is a biotechnology company dedicated to enabling the widespread application of human cells as medicine. ViaCell markets ViaCord, a product offering through which families can preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases. ViaCell is also working to leverage its commercial infrastructure and product development capabilities by developing ViaCyteSM, a product candidate being studied for its potential to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell also conducts research and development primarily to investigate other potential therapeutic uses of umbilical cord blood-derived stem cells and on technology for expanding populations of these cells. ViaCell's pipeline is focused in the areas of cancer, cardiac disease, and diabetes. Additional information about ViaCell is available online at http://www.viacellinc.com. Additional information about ViaCord is also available at http://www.viacord.com.
     
     
    # # #
     
    For further information:
     
    PerkinElmer Investor Contact: 
    Michael A. Lawless
    (781) 663-5659
     
    PerkinElmer Media Contact:
    Kevin J. Lorenc
    (781) 663-5701
     
     
    PerkinElmer, Inc.
    940 Winter Street
    Waltham, MA 02451 USA
    Phone: 781-663-6900
    Fax: 781-663-5985
  12. 10/1/07 PerkinElmer to Expand Genetic Screening Business Through Inquisition of ViaCell

    FOR IMMEDIATE RELEASE
    10/1/07

    PERKINELMER TO EXPAND GENETIC SCREENING BUSINESS  THROUGH ACQUISITION OF VIACELL

    Expands Neonatal Product Range and Clinical Reach
     
    WALTHAM, Mass. and CAMBRIDGE, Mass. -- PerkinElmer, Inc. (NYSE: PKI), a global technology leader in Health Sciences, and ViaCell, Inc. (Nasdaq: VIAC), a biotechnology company specializing in the collection and preservation of umbilical cord blood stem cells, announced today the signing of a definitive agreement under which PerkinElmer plans to acquire ViaCell. The addition of ViaCell’s ViaCord® product offering for the preservation of umbilical cord blood and its highly qualified sales and marketing organization are expected to significantly expand PerkinElmer’s offerings and reach in neonatal and prenatal markets.
     
    Under the agreement, PerkinElmer will commence a cash tender offer to purchase all of the outstanding shares of ViaCell for $7.25 per share, for an aggregate purchase price of approximately $300 million, or $260 million net of cash. The transaction is expected to close in the fourth quarter of 2007. PerkinElmer  anticipates this transaction will be slightly dilutive to its non-GAAP 2008 adjusted earnings per share, and accretive to its non-GAAP 2009 adjusted earnings per share.
     
    “ViaCell has built a high growth business based on innovative umbilical cord blood preservation technology, with a strong, established market presence,” said Gregory L. Summe, Chairman and Chief Executive Officer, PerkinElmer , Inc. “This is an important investment to continue expanding our Genetic Screening business. We are excited by the prospect of combining ViaCell with our existing prenatal and neonatal screening services, with an enhanced ability to reach obstetric professionals and prospective parents throughout the United States.”
     
    PerkinElmer is the world leader in neonatal screening solutions, with the ability to screen for more than 50 genetic disorders,” added Robert F. Friel, President and Chief Operating Officer, PerkinElmer, Inc.  “A growing number of disorders – which today includes blood disorders, such as sickle cell anemia, and metabolic disorders – are treatable using the cord blood stem cells gathered and preserved through ViaCell’s ViaCord offering. By bringing both the screening and therapeutic benefits of these two businesses together, we can offer a more comprehensive solution to patients and practitioners.”
    “We are excited by the opportunity to increase access to our products by leveraging PerkinElmer’s global reach and resources,” said Marc D. Beer, President and Chief Executive Officer, ViaCell, Inc. “We believe this transaction will maximize value to our shareholders while continuing to accelerate the growth of the ViaCord business and the progress of future product development.”
     
    ViaCell offers significant expertise in the collection, testing, processing and preservation of umbilical cord blood stem cells. ViaCell has built a dynamic sales organization in the U.S. which calls regularly on more than 17,000 obstetricians and interacts monthly with hundreds of thousands of prospective parents. Currently, ViaCell markets ViaCord, a product offering that allows expectant families the opportunity to preserve their baby’s umbilical cord blood at the time of birth for potential medical use by the child or a related family member. Cord blood has been shown to be effective in treating over 40 diseases including blood cancers and certain genetic diseases. To date, ViaCord has preserved over 130,000 newborns’ umbilical cord blood. ViaCord sales are expected to be in the mid- to high-60 million dollar range in 2007. It is estimated that the U.S. market for family cord blood banking could reach more than $1 billion. PerkinElmer anticipates divesting ViaCell’s therapeutic businesses.
     
    In addition to newborn screening solutions, PerkinElmer continues to build its genetic screening portfolio to provide the most accurate assessment of fetal and maternal health to women and their healthcare practitioners. PerkinElmer now offers Ultra-Screen®, a first-trimester prenatal screening protocol designed to provide patient-specific risk assessment for certain chromosomal abnormalities, through its NTD Laboratories division. The Company also holds a global licensing agreement to develop assay kits for the ADAM12 biochemical marker, which has broad potential in maternal health screening for fetal chromosomal abnormalities, and has secured global rights for Placental Protein 13 (PP13), a new maternal serum marker currently under investigation that has shown potential for early detection of preeclampsia in low-risk groups.
     
    The acquisition has been unanimously approved by the board of directors of each company and is subject to customary closing conditions, including clearance under Hart Scott Rodino.
     
    Related to the transaction, Merrill Lynch & Co. is acting as financial advisor to PerkinElmer, and UBS Investment Bank is acting as financial advisor to ViaCell. Wilmer Cutler Pickering Hale and Dorr LLP is acting as legal counsel to PerkinElmer and Ropes & Gray LLP is acting as legal counsel to ViaCell.
     
    Conference Call
     
    The management teams of PerkinElmer and ViaCell will be hosting a conference call and simultaneous webcast to discuss the transaction today, Monday, October 1, 2007, at 5:30 p.m. Eastern Time (ET). The dial-in number is +1.617.213.8834 and the passcode is 89545028. To access the webcast, go to the Investor Relations sections on PerkinElmer’s Web site at www.perkinelmer.com or ViaCell’s Web site at www.viacellinc.com. A replay of the call will be available for seven days by dialing +1.617.801.6888 and using the passcode 73366935, or by accessing the Investor Information pages at www.perkinelmer.com or www.viacellinc.com.
     
    Important Additional Information Will Be Filed with the Securities Exchange Commission (SEC)
     
    This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of ViaCell, Inc. PerkinElmer has not commenced the tender offer for shares of ViaCell stock described in this press release.
     
    At the time the tender offer is commenced, PerkinElmer will file with the SEC and mail to ViaCell’s stockholders a Tender Offer Statement on Schedule TO and related exhibits, including the offer to purchase, letter of transmittal and other related documents, and ViaCell will file with the SEC and mail to its stockholders a Tender Offer Solicitation/Recommendation Statement on Schedule 14D-9 in connection with the transaction. These will contain important information about PerkinElmer, ViaCell, the transaction and other related matters. Investors and security holders are urged to read each of these documents carefully when they are available.
     
    Investors and security holders will be able to obtain free copies of the Tender Offer Statement, the Tender Offer Solicitation/Recommendation Statement and other documents filed with the SEC by PerkinElmer and ViaCell through the Web site maintained by the SEC at www.sec.gov. In addition, investors and security holders will be able to obtain free copies of these documents by contacting the Investor Relations departments of PerkinElmer or ViaCell.
     
    Cautionary Note Regarding Forward-Looking Statements
     
    Statements in this press release regarding the proposed transaction between PerkinElmer and ViaCell, the expected timetable for completing the transaction, future financial and operating results, benefits and synergies of the transaction, future opportunities for and expansion of the combined company, the expected impact of the anticipated transaction on PerkinElmer’s earnings, the extent to which the transaction advances PerkinElmer’s business, expectations for growth of the family cord blood banking market and the ViaCord business, the advancement of ViaCell’s product candidates and plans for ViaCell’s therapeutic and research business, and any other statements about PerkinElmer or ViaCell managements’ future expectations, beliefs, goals, plans or prospects constitute forward-looking statements. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” estimates and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the possibility that certain closing conditions to the transaction will not be met; the ability to consummate the transaction, the ability of PerkinElmer to successfully integrate ViaCell’s operations and employees; the ability to realize anticipated synergies and cost savings; and the other factors described in PerkinElmer’s Annual Report on Form 10-K for the year ended December 31, 2006, and in ViaCell’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, each of which has been filed with the SEC. Except as otherwise required by law, PerkinElmer and ViaCell disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
     
    Use of Non-GAAP Financial Measures
     
    This announcement contains the non-GAAP financial measure “adjusted earnings per share.” PerkinElmer uses the term “adjusted earnings per share” to refer to GAAP earnings per share, excluding discontinued operations, amortization of intangible assets, inventory fair value adjustments, in-process research and development charges, deferred revenue adjustments, and other significant adjustments related to business acquisitions, gains on settlement of insurance claim, restructuring and lease charges, stock option expense and certain other gains and losses. PerkinElmer believes that this non-GAAP measure, when taken together with our GAAP financial measure, allows it and its investors to analyze the costs of producing and selling our products and the performance of its internal investments in technology and internal operating structure, to evaluate the long-term profitability trends of its core operations and to calculate the underlying value of the core business on a dilutive share basis, which is a key measure of the value of PerkinElmer used by its management and it believes used by investors as well. Adjusted earnings per share also facilitates the overall analysis of the value of the Company and the core measure of the success of its operating business model as compared to prior and future periods and relative comparisons to its peers. PerkinElmer excludes discontinued operations, amortization of intangible assets, inventory fair value adjustments, in-process research and development charges and other significant adjustments related to business acquisitions, gains on settlement of insurance claim, restructuring and lease charges, stock option expense and certain other gains and losses as these items do not represent what PerkinElmer’s management and what it believes its investors consider to be costs of producing its products, investments in technology and production, and costs to support its internal operating structure, which could result in overstating or understating to its investors the performance of its operations.
     
    About PerkinElmer
     
    PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.55 billion in 2006, has 8,500 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
     
    About ViaCell
     
    ViaCell, Inc. is a biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company markets ViaCord, a product offering through which families can preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases. The Company is also working to leverage its commercial infrastructure and product development capabilities by developing ViaCyteSM, a product candidate being studied for its potential to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell also conducts research and development primarily to investigate other potential therapeutic uses of umbilical cord blood-derived stem cells and on technology for expanding populations of these cells. ViaCell's pipeline is focused in the areas of cancer, cardiac disease, and diabetes. Additional information about ViaCell is available online at http://www.viacellinc.com. Additional information about ViaCord is also available at http://www.viacord.com.
     
    # # #
     
    For further information:
     
    PerkinElmer Investor Contact:
    Michael A. Lawless
    (781) 663-5659
     
    PerkinElmer Media Contact:
    Kevin J. Lorenc
    (781) 663-5701
     
    PerkinElmer, Inc.
    940 Winter Street
    Waltham, MA 02451 USA
    Phone: 781-663-6900
    Fax: 781-663-5985
  13. ViaCell Announces Expansion of ViaCord Processing Laboratory

    FOR IMMEDIATE RELEASE

    9/18/07

     


    Cambridge, MA (September 18, 2007) ViaCell, Inc. (Nasdaq: VIAC) today announced that it is expanding its ViaCord Processing Facility (VPL), the Company’s state-of-the-art cord blood processing and storage facility. The expansion of VPL will support anticipated future demand of ViaCord®, its product offering for the preservation of cord blood. ViaCell will conduct renovations in the newly leased space in order to meet its planned cord blood processing and storage needs for the coming years. The expansion is expected to be completed in the first quarter of 2008.

     

    “The expansion of our cord blood processing facility will more than double our storage capacity and positions us to meet increasing demand for ViaCord,” said Jim Corbett, President of ViaCell Reproductive Health.

     

    ViaCord has been successfully processing cord blood since 1995 and processing cord blood at VPL since 2002. This facility is AABB accredited and incorporates industry-leading standards, including a closed processing system, storage of cord blood with multiple attached segments, use of the only-FDA cleared process automation equipment and laboratory testing performed in accordance with Clinical Laboratory Improvement Amendments (CLIA) regulations.

     

    About Umbilical Cord Blood

     

    Umbilical cord blood is a valuable, non-controversial source of stem cells with proven therapeutic effect in treating over 40 diseases. These diseases include various forms of cancer, such as Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin’s lymphoma; certain bone marrow failure syndromes, such as severe aplastic anemia and Diamond Blackfan anemia; certain blood disorders such as sickle cell anemia, thalassemia; and other genetic disorders. Over 8,000 cord blood transplants have been performed worldwide. Studies have shown that umbilical cord blood transplants from a family member, rather than from a non-relative, have a significantly higher survival rate than transplants from an unrelated donor.

     

    About ViaCord

     

    ViaCord allows expectant families the opportunity to preserve their baby’s umbilical cord blood for potential medical use by the child or a related family member. The child’s cord blood is collected at the time of birth in the only FDA-approved cord blood collection bag suitable for use in a sterile field. To date, ViaCord has preserved over 130,000 newborn’s umbilical cord blood. Additional information about ViaCord is available online at http://www.viacord.com.

     

    About ViaCell

     

    ViaCell, Inc. is a biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company markets ViaCord®, a product offering through which families can preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases. The Company is also working to leverage its commercial infrastructure and product development capabilities by developing ViaCyteSM, a product candidate being studied for its potential to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell also conducts research and development primarily to investigate other potential therapeutic uses of umbilical cord blood-derived stem cells and on technology for expanding populations of these cells. ViaCell’s pipeline is focused in the areas of cancer, cardiac disease, and diabetes. Additional information about ViaCell is available online at http://www.viacellinc.com.

     

    Risks of Forward-Looking Statements

     

    This press release contains forward-looking statements regarding the Company's expectations with respect to its ViaCord product offering and timing for completion of the expansion of ViaCord Processing Laboratory. These statements are based on management's current expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from the Company's current expectations. For example, the Company's expectations with respect to ViaCord may be negatively affected by the impact of competition in the umbilical cord preservation industry, any changes in market acceptance for family cord blood banking, any slowing of growth of the family cord blood banking market, the impact of any potential adverse outcome in pending patent infringement litigation related to the cord blood preservation business, any further impact of a third party's dispute with Mothers Work related to the rights granted to the Company, including if a court were to vacate the arbitrator's decision, and any unexpected material issues, delays or failures in the collection, processing or storage of umbilical cord blood by the Company or others in the industry. In addition, the Company’s expectations for the completion of the expansion may be impacted by, among other things, unexpected delays in planned construction work in the new space and in obtaining the requisite permits and other approvals necessary to complete the construction work and begin operations in the new space. For more detailed information on the risks and uncertainties associated with these forward-looking statements and the Company's other activities, see the periodic reports filed by the Company with the Securities and Exchange Commission. The Company does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

     

    ViaCell® and ViaCord® are registered trademarks and ViaCyteSM is a service mark of ViaCell, Inc.

     

    ###

  14. ViaCell Prevails Over PharmaStem in Federal Circuit Patent Appeal

    FOR IMMEDIATE RELEASE

    7/9/07

     


     

    Court Upholds Finding of Non-Infringement and Invalidates Patents

     

    Cambridge, MA (July 9, 2007)  ViaCell, Inc. (Nasdaq: VIAC) today announced that the U.S. Court of Appeals for the Federal Circuit has ruled in favor of ViaCell in a patent infringement suit brought against the Company and other defendants by PharmaStem Therapeutics, Inc. The Federal Circuit upheld an earlier decision by the U.S. District Court for the District of Delaware that ViaCell, through its marketing of ViaCord®, a product offering through which families can preserve their baby’s umbilical cord blood at the time of birth for possible future medical use, does not infringe PharmaStem’s U.S. Patent No. 5,192,553 (‘553) and U.S. Patent No. 5,004,681 (‘681), which relate to certain aspects of collection, cryopreservation, storage and use of hematopoietic stem cells from umbilical cord blood. The court also found the ‘553 and the ‘681 patents invalid based on prior art.

     

    “We are extremely pleased with this ruling and believe this is a major step toward bringing closure to the suits brought against us,” said Marc D. Beer, President and Chief Executive Officer of ViaCell.

     

    A copy of the Federal Circuit’s decision is available online at http://www.fedcir.gov.

     

    Background on Litigation

     

    In 2002, PharmaStem brought suit against ViaCell and several other defendants alleging infringement of the ‘553 and ‘681 patents. The patents relate to certain aspects of the collection, cryopreservation, storage, and use of hematopoietic stem cells from umbilical cord blood. In 2004, a District Court judge, in overturning a previous jury verdict against ViaCell and the other defendants in this case, found that PharmaStem had failed to prove infringement. PharmaStem appealed the decision. In April 2006, the U.S. Court of Appeals for the Federal Circuit heard oral argument in the appeal. In 2004, PharmaStem brought a second suit against ViaCell and the other defendants alleging infringement of U.S. Patent Nos. 6,461,645 and 6,569,427. These patents have similar claims to the ‘553 and ‘681 patents. The second case has been stayed pending decisions from the Federal Circuit on the appeal and re-examinations of the patents by the United States Patent and Trademark Office.

     

    About ViaCell

     

    ViaCell, Inc. is a biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company markets ViaCord®, a product offering through which families can preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases. ViaCell also conducts research and development primarily to investigate other potential therapeutic uses ofumbilical cord blood-derived stem cells and on technology for expanding populations of these cells. ViaCell’s pipeline is focused in the areas of cancer, cardiac disease, diabetes and fertility. For more information about ViaCell, visit our website at http://www.viacellinc.com.

     

    - more -

     

    This press release contains forward-looking statements regarding the PharmaStem litigation. Such statements are based on management's current beliefs and expectations. There are a number of risks and uncertainties that could cause actual results to differ materially from management's current beliefs and expectations. The second case brought by PharmaStem based on the ‘645 and ‘427 patents may continue. PharmaStem may seek to appeal the decision of the U.S. Court of Appeals. In such an event, the decision of the U.S. Court of Appeals may be overturned or the case may be remanded to the District Court. We may ultimately be found to infringe valid claims of the PharmaStem patents, in which case we could have a significant damages award entered against us or could face an injunction which could prohibit us from further engaging in the umbilical cord stem cell business absent a license from PharmaStem. We may also incur significant additional legal fees and expenses in connection with this litigation. For more information on the risks and uncertainties associated with this litigation or with the Company and its products and programs, see the factors set forth under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2007, which is on file with the Securities and Exchange Commission and which factors are incorporated herein by reference. ViaCell does not undertake any obligation to update forward-looking statements.

     

    ViaCell® and ViaCord® are registered trademarks of ViaCell, Inc.

     

    ###

  15. ViaCord and Children’s Hospital Oakland Research Institute Announce 100th Cord Blood Transplant

    FOR IMMEDIATE RELEASE

    6/13/07


     

     

    Represents Most Related Cord Blood Transplant Experience

     

    Cambridge, MA and Oakland, CA (June 13, 2007) ViaCord®, the umbilical cord blood preservation division of ViaCell, Inc. (Nasdaq: VIAC), and Children’s Hospital Oakland Research Institute (CHORI) today announced that they have achieved their 100th umbilical cord blood transplant. The 100th transplant was a sibling transplant to treat Severe Combined Immunodeficiency (SCID), commonly known as “bubble boy” disease. This historic milestone includes transplants through cord blood collected, preserved and stored with ViaCord and transplants using cord blood stored through CHORI’s Sibling Donor Cord Blood Program.

     

    In 2006, ViaCell and CHORI combined their efforts in the area of directed transplants for sibling donor umbilical cord blood to form the Sibling Connection Program. This program provides ViaCord’s comprehensive cord blood collection, processing and five years of storage at no cost to families who have a child in need of a transplant and meet the other requirements of the program.

     

    ViaCord and CHORI have the most related cord blood transplant experience. As the leading provider of related cord blood for directed transplantation, ViaCord and CHORI offer transplant physicians and families confidence the cells are processed and stored in a high quality manner at ViaCord’s state-of-the-art cord blood processing laboratory.

     

    “ViaCord stored our younger son’s umbilical cord blood which was later used to treat his brother for sickle cell anemia,” said Ms. Tammy Witherspoon, mother of two in McComb, Mississippi. “After many years of suffering, our older son is now cured of the disease. We are so grateful for this medical advance and urge families to learn more about the potential of umbilical cord blood.”

     

    “The therapeutic effect cord blood has in treating a wide range of diseases supports the need to educate all birthing families about cord blood preservation so they can adequately consider this unique opportunity,” said Brent N. Davidson, MD. Service Chief, Women’s Services, Henry Ford Hospital, West Bloomfield, Michigan. “Moreover, it is important that families understand the clinical advantage of using cord blood stem cells from a related source should they need the preserved cord blood for a future transplant.”

     

    The majority of the ViaCord and CHORI transplants were used to treat siblings for a variety of diseases, including various types of leukemia, Fanconi anemia, sickle cell anemia, and thalassemia, among others. Additionally, several autologous transplants (transplants using the child’s own cord blood) were performed to treat diseases such as severe aplastic anemia and neuroblastoma.

     

    In February 2007, Dr. Mark Walters, Director of the Blood & Marrow Transplant Program at Children’s Hospital & Research Center Oakland and Medical Director of ViaCord’s cord blood processing laboratory, presented findings that related umbilical cord blood units are an effective graft source for treatment in a variety of diseases requiring transplantation. As presented at the American Society of Blood and Marrow Transplantation Meeting, transplant outcomes from units processed and stored through CHORI’s Sibling Donor Cord Blood Program compared favorably with bone marrow transplantation from sibling donors. In 60 patients evaluated, the median time to neutrophil recovery was 22 days. The overall survival at one year was 80%. Acute graft-versus-host-disease, or GVHD (greater than Grade 1), was observed in 25% of allogeneic recipients and only 4% had chronic GVHD. In contrast, 41% of recipients who receive unrelated transplants develop acute GVHD and 25% develop chronic GVHD. ViaCord expects to publish its updated transplant findings at future medical meetings.

     

    About Umbilical Cord Blood

     

    Umbilical cord blood is a valuable, non-controversial source of stem cells with proven therapeutic effect in treating over 40 diseases. These diseases include cancers such as Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin’s lymphoma, certain bone marrow failure syndromes such as severe aplastic anemia and Diamond Blackfan anemia, certain blood disorders such as sickle cell anemia, thalassemia and other genetic disorders. Over 8,000 cord blood transplants have been performed worldwide. Studies have shown that umbilical cord blood transplants from a family member, rather than from a non-relative, have a significantly higher survival rate than transplants from an unrelated donor.

     

    About ViaCord

     

    ViaCord allows expectant families the opportunity to preserve their baby’s umbilical cord blood for potential medical use by the child or a related family member. The child’s cord blood is collected at the time of birth in the only FDA-approved cord blood collection bag suitable for use in a sterile field. To date, over 115,000 families have preserved their children’s umbilical cord blood through ViaCord. The ViaCord Processing Laboratory, located in Hebron, Kentucky, is an AABB accredited cord blood facility. Additional information about ViaCord is available online at http://www.viacord.com.

     

    Research at Children’s Hospital & Research Center Oakland, CA

     

    Research efforts at Children’s Hospital & Research Center Oakland are coordinated through Children’s Hospital Oakland Research Institute (CHORI). Children’s Hospital Oakland is Northern California’s only freestanding and independent children’s hospital. CHORI’s internationally renowned biomedical research facility brings together seven centers of excellence that are devoted to clinical and basic science research to treat and prevent disease. CHORI has approximately 300 investigators and an annual budget of more than $47 million, primarily supplied by National Institutes of Health grants. The institute is a leader in translational research, bringing bench discoveries to bedside applications. These include providing cures for blood diseases, developing new vaccines for infectious diseases, and discovering new treatment protocols for previously fatal or debilitating conditions such as cancers, sickle cell disease, AIDS/HIV, pediatric obesity, hemophilia and cystic fibrosis.

     

    About ViaCell

     

    ViaCell, Inc. is a biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company markets ViaCord®, a product offering through which families can preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases. ViaCell also conducts research and development primarily to investigate other potential therapeutic uses of umbilical cord blood-derived cells and on technology for expanding populations of these cells. ViaCell’s pipeline is focused in the areas of cancer, cardiac disease, diabetes and fertility. For more information about ViaCell, visit our website at http://www.viacellinc.com.

     

    ViaCell® and ViaCord® are federally registered trademarks of ViaCell, Inc.

     

    ###

  16. Federal Court in Delaware reverses jury's judgment and rules in favoof ViaCell and against PharmaStem

    FOR IMMEDIATE RELEASE
    12/6/04


    BOSTON, Dec. 16 /PRNewswire/ -- ViaCell, Inc. announced today that a Federal Court in Delaware reversed the jury's judgment completely and ruled in favor of ViaCell and against PharmaStem on all of PharmaStem's claims in the patent infringement case brought by PharmaStem in Delaware and relating to ViaCell's ViaCord umbilical cord blood preservation product. In particular, the Court's Order of this week reversed a prior jury verdict with respect to the only patent remaining in the case, U.S. Patent No. 5,004,681, and ruled in favor of ViaCell on PharmaStem's claim of infringement. In September 2004, the Court reversed the jury's verdict and ruled in favor of ViaCell and against PharmaStem on PharmaStem's claim of infringement of the only other patent in that case, U.S. Patent No. 5,192,553. Further, as a result of the Court's action, PharmaStem's recent motion for a preliminary injunction against ViaCell was dismissed.

    "We are delighted with the court's decision and have contended from the beginning that the original verdict was contrary to the evidence presented at the trial," said Marc Beer, CEO of ViaCell. "This decision, combined with the Court's earlier decision, signify a complete victory for ViaCell in the trial on PharmaStem's claims of infringement of the '681 and '553 patents."

    Beer further stated, "When selecting a cord blood banking company, families should make that choice based on the commitment to science and quality and the experience of the company."

    ViaCell's Viacord umbilical cord blood preservation product is used primarily for pediatric bone marrow transplants. The Company is also developing a pipeline of proprietary product candidates intended to address cancer, infertility, and cardiac diseases. ViaCell's proprietary technologies include Selective Amplification technology, which the Company believes will enable the development of stem cell products based on the isolation, purification and significant expansion of targeted stem cell populations. ViaCell is using these assets to develop a cord blood-derived stem cell therapeutic, CB001, the Company's lead stem cell therapy product candidate, which is currently in a Phase I clinical trial.


    CONTACT: Marc D. Beer, CEO of ViaCell, Inc., +1-617-914-3556, or Media, Justin Jackson of Burns McClellan, +1-212-213-0006, ext. 327, for ViaCell

    SOURCE ViaCell, Inc.

    -0- 12/16/2004

    /CONTACT: Marc D. Beer, CEO of ViaCell, Inc., +1-617-914-3556, or Media, Justin Jackson of Burns McClellan, +1-212-213-0006, ext. 327, for ViaCell /

    /First Call Analyst: /

    /FCMN Contact: /

    /Web site: http://www.viacord.com /

    CO: ViaCell, Inc.; PharmaStem

    ST: Massachusetts

    IN: HEA MTC BIO

    SU: LAW 

  17. ViaCell Implements Automation Technology at ViaCord Processing Laboratory

    FOR IMMEDIATE RELEASE
    1/08/07


    Technology Represents First FDA Cleared System for Cord Blood Processing

     

    Cambridge, MA (January 8, 2007) ViaCell, Inc. (Nasdaq: VIAC) today announced that it is integrating automation into its existing closed processing system at its processing laboratory for ViaCord®, a product offering that allows expectant families the opportunity to preserve their baby’s umbilical cord blood for potential use by the child or related family member. The automation technology is the SEPAX Cord Blood Processing System from Biosafe SA, a closed and sterile processing system that efficiently harvests stem cells from cord blood in a large-scale processing environment. SEPAX is the only FDA cleared cord blood processing system. Biosafe received FDA clearance in January 2007 and European CE mark approval in 2001.

     

    “Each cord blood unit varies in volume and cell count. As a result, we believe the SEPAX automation technology, in combination with our long-standing closed processing system, will allow us to continue offering all families a high quality product with the efficiency required to meet increasing demand for ViaCord,” said Jim Corbett, President of ViaCell Reproductive Health. “SEPAX, together with our exclusive FDA-approved collection bag, provides families advanced technology during every step of the cord blood banking process.”

     

    Mr. Corbett added, “SEPAX is a proven technology with a proven transplant record. The SEPAX system is widely used in Europe and elsewhere with over 100,000 units processed using this technology, from which hundreds of transplants have been performed.”

     

    “We are very pleased to have one of the largest and most respected family cord blood banks adopting the SEPAX System,” said Claude Fell, President and Chief Executive Officer of Biosafe SA. “SEPAX has earned a reputation for safety and performance over a number of years of routine operation in leading stem cell processing facilities and hematology laboratories around the world.”

     

    About ViaCord®

    ViaCord is a product offering that allows expectant families the opportunity to preserve their baby’s umbilical cord blood for potential use by the child or a related family member. ViaCord recently launched the first and only FDA cleared cord blood collection bag suitable for use in a sterile field. In addition, ViaCord uses multi-compartment cryobags as part of its closed processing system to ensure that cells are processed in a manner that meets U.S. FDA regulations designed to prevent contamination and error. Cells stored in cryobags have been used in more than 99% of all cord blood transplants. Stem cells derived from umbilical cord blood are currently a treatment option for over 40 diseases, including cancers such as acute lymphoblastic leukemia and Non-Hodgkins lymphoma, certain bone marrow failure syndromes such as severe aplastic anemia and neuroblastoma, certain blood disorders such as sickle cell anemia and other metabolic diseases such as Hurler syndrome. Studies have shown that umbilical cord stem cell transplants from a related donor have a significantly higher survival rate than transplants from an unrelated donor.

    -more-

    About ViaCell

    ViaCell is a biotechnology company focused on enabling the widespread use of human cells as medicine. The Company is developing a pipeline of proprietary stem cell product candidates intended to address cancer, cardiac disease, and diabetes. CB001, its lead cord blood derived stem cell therapy product candidate, is being developed for hematopoietic stem cell transplantation in patients affected by a variety of cancers. In addition to its therapeutic development programs, ViaCell’s Reproductive Health Business commercializes ViaCord®, a product that offers expecting families the option of preserving their baby’s umbilical cord blood. The Company is working to leverage its commercial infrastructure and product development capabilities by developing ViaCyteSM, its investigational product intended to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell is headquartered in Cambridge, Massachusetts with a processing and storage facility in Kentucky and additional research and development operations in Singapore. Additional information about ViaCell is available online at http://www.viacellinc.com.

     

    About Biosafe

    Biosafe is a privately-held company based in the Lake Geneva region of Switzerland. Biosafe, through its Sepax technology, is the world’s leading supplier of automated cord blood processing systems and is present in over 30 countries. The Sepax System is used by a majority of Netcord members, an organization that brings together internationally-renowned public cord blood banks.

    Further information about Biosafe and the Sepax System is available at www.biosafe.ch or +41 22 365 2727. The Sepax System is distributed in N. America by GenesisBPS - www.genesisbps.com or 866-71-BLOOD (25663) or 201-708-1400.

     

    This press release contains forward-looking statements regarding the anticipated future demand of the ViaCord business and expected impact of the SEPAX system. These statements are based on management's current expectations. The growth of the ViaCord business is subject to a number of risks and uncertainties. Factors which could cause actual results to differ materially from the Company's current expectations include, but are not limited to: the impact of competition in the umbilical cord preservation industry, the impact of any potential adverse outcome in pending patent infringement litigation related to the cord blood preservation business, and any other unexpected material issues, delays or failures in the collection, processing or storage of umbilical cord blood by the Company. The Company’s ability to achieve expected benefits from use of the SEPAX system may be impacted by a number of factors, including unexpected technical hurdles or other problems or issues that may arise during implementation and use. For more information on the risks and uncertainties associated with the Company, its financial performance, its products and programs, and pending litigation, see the factors set forth under the heading "Risk Factors That May Affect Results" in the Company's Quarterly Report on Form 10-Q for the quarter ending September 30, 2006, which is on file with the Securities and Exchange Commission and which factors are incorporated herein by reference. ViaCell does not undertake any obligation to update forward-looking statements.

     

    ViaCell® and ViaCord® are federally registered trademarks and ViaCyteSM is a service mark of ViaCell, Inc. All other trademarks are those of the respective owners.

    ###

  18. ViaCell Announces New Office Actions Rejecting PharmaStem Patent Claims

    FOR IMMEDIATE RELEASE
    5/30/06

     

    Cambridge, MA (May 30, 2006)ViaCell, Inc. (Nasdaq: VIAC) today announced that, following a re-examination, the United States Patent and Trademark Office (PTO) issued two new office actions rejecting all of the claims of PharmaStem Therapeutics Inc.’s U.S. Patent No. 5,192,553 and U.S. Patent No. 6,569,427 as being unpatentable over prior art. Recently, the PTO issued initial office actions rejecting all the claims of PharmaStem Patent Nos. 5,004,681 and 6,461,645. All of these patents relate to certain aspects of the collection, cryopreservation, storage and use of hematopoietic stem cells from umbilical cord blood and have been asserted against ViaCell and several other defendants by PharmaStem in pending patent infringement cases.

     

    “We are very pleased with these developments,” said Anne Marie Cook, General Counsel and Senior Vice President, Business and Corporate Development of ViaCell. “We believe the PTO’s actions support our position that the patents are invalid based on prior art.”

     

    Background on PharmaStem Litigation

    In 2002, PharmaStem brought suit against ViaCell and several other defendants alleging infringement of U.S. Patent Nos. 5,192,553 and 5,004,681. In 2004, PharmaStem brought a second suit against ViaCell and the other defendants alleging infringement of U.S. Patent Nos. 6,461,645 and 6,569,427. Separately, the PTO ordered re-examinations of these four patents based on prior art.

     

    In 2004, a District Court judge, in overturning a previous jury verdict in the first case, found that PharmaStem had failed to prove infringement. PharmaStem appealed the decision and the U.S. Court of Appeals for the Federal Circuit heard oral argument in the appeal on April 4, 2006. The second case has been stayed pending decisions from the Federal Circuit on the appeal and the PTO on the patent re-examinations.

     

    In 2003, the European Patent Office revoked all the PharmaStem patent claims on collecting, freezing and using blood from umbilical cord blood for transplantation and therapeutic treatments.

     

    About ViaCell, Inc.

    ViaCell is a biotechnology company focused on enabling the widespread use of human cells as medicine. The Company is developing a pipeline of proprietary stem cell product candidates intended to address cancer, cardiac disease, and diabetes. CB001, its lead cord blood derived stem cell therapy product candidate, is being developed for hematopoietic stem cell transplantation in patients affected by a variety of cancers. In addition to its therapeutic development programs, ViaCell’s reproductive health business commercializes ViaCord®, a product that offers expecting families the option of preserving their baby’s umbilical cord blood. The Company is working to leverage its commercial infrastructure and product development capabilities by developing ViaCyteSM, its investigational product intended to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell is headquartered in Cambridge, Massachusetts with a processing and storage facility in Kentucky and additional research and development operations in Singapore. Additional information about ViaCell is available online at http://www.viacellinc.com.

    - more -

    This press release contains forward-looking statements regarding the possible outcome of litigation. Such statements are based on management's current beliefs and expectations. There are a number of risks and uncertainties that could cause actual results to differ materially from management’s current beliefs and expectations. A PTO Office Action is not a final decision. PharmaStem will have the right to respond to the Office Action and may either amend the patent claims to try to avoid prior art or may challenge the decision at the PTO or through appeal. There is no assurance that PharmaStem will not be successful in these efforts. There is also no assurance that the Court of Appeals will find in ViaCell’s favor in the appeal of the pending litigation. The Court of Appeals could demand a retrial or decide to reinstate the jury verdict. For more information on the risks and uncertainties associated with this litigation or with the Company and its products and programs, see the factors set forth under the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2006, which is on file with the Securities and Exchange Commission and which factors are incorporated herein by reference. ViaCell does not undertake any obligation to update forward-looking statements.

     

    ViaCell® and ViaCord® are registered trademarks and ViaCyteSM is a service mark of ViaCell, Inc.

     

    ###

  19. ViaCell and Children’s Hospital Oakland Research Institute Expand Sibling Cord Blood Donor Program

    FOR IMMEDIATE RELEASE
    5/30/06


    Cambridge, MA, (May 30, 2006)  ViaCell, Inc. (Nasdaq: VIAC) and Children’s Hospital Oakland Research Institute (CHORI) today announced an agreement to combine their efforts in the area of directed transplants of sibling donor cord blood. The combined program brings together CHORI’s nation-wide program and transplant experience with the high quality processing and customer service offered by ViaCord®, ViaCell’s product offering for the preservation and storage of cord blood for related use. The CHORI/ViaCord sibling transplant program offers umbilical cord blood preservation services to expectant parents who have a child in need of a transplant for a disease currently treatable with cord blood stem cells. CHORI and ViaCord’s combined experience includes nearly 80 related cord blood transplants.

     

    Under the agreement, ViaCell will manage the combined program and process and store new cord blood units collected for transplant under the sibling donor program at ViaCord’s Processing Laboratory. ViaCell will also have responsibility for releasing cord blood units called for transplant and assist families through the process. CHORI will continue to educate the transplant community on the directed transplant program and the importance of cord blood as well as monitor and evaluate the program. Financial terms were not disclosed.

     

    “The combined transplants of CHORI and ViaCord establish us as a leading provider of related cord blood stem cells for directed transplantation,” stated Mary T. Thistle, Senior Vice President, Business Development, ViaCell Reproductive Health. “I believe that through this partnership and working with the entire team at CHORI, led by Dr. Bertram Lubin and Dr. Mark Walters, we have the ability to expand our educational program to reach a broader range of physicians who treat patients who may benefit from cord blood stem cells.”

     

    “I am delighted that together with ViaCell we have the opportunity to expand the sibling cord blood program to more patients,” said Dr. Bertram H. Lubin, Director of Medical Research at CHORI. “After thorough due diligence in assessing the field, I am confident that ViaCell processes cells in the highest quality manner, suitable for transplantation.”

     

    About ViaCord

    ViaCord is a product offering that allows expectant families the opportunity to preserve their baby’s umbilical cord blood for potential use by the child or a related family member. Stem cells derived from umbilical cord blood are currently a treatment option for over 40 diseases, including cancers such as acute lymphoblastic leukemia and Non-Hodgkins lymphoma, certain bone marrow failure syndromes such as severe aplastic anemia and neuroblastoma, certain blood disorders such as sickle cell anemia and other metabolic diseases such as Hurler syndrome. Studies have shown that umbilical cord stem cell transplants from a related donor have a significantly higher survival rate than transplants from an unrelated donor. ViaCord uses multi-compartment cryobags as part of its closed processing system to ensure that cells are processed in a manner that meets U.S. FDA regulations designed to prevent contamination and error. Cryobags have been used in more than 99% of all cord blood transplants.

     

    About CHORI

    Children’s Hospital Oakland Research Institute is an internationally renowned biomedical research institute, CHORI bridges basic science and clinical research in the treatment and prevention of human disease. CHORI is a leader in translational research, providing cures for blood diseases, developing new vaccines for infectious diseases, and discovering new treatment protocols for previously fatal or debilitating conditions.

     

    The CHORI Sibling Cord Blood Donor Program is a national program designed to provide a unique treatment option to families with children suffering from cancer, leukemia, hemoglobinopathies and other transplant-treatable illnesses. CHORI’s Sibling Donor Cord Blood Program facilitates the collection of umbilical cord blood at the time of delivery from newborn siblings of children who might benefit from a cord blood transplant.

     

    About ViaCell, Inc.

    ViaCell is a biotechnology company focused on enabling the widespread use of human cells as medicine. The Company is developing a pipeline of proprietary stem cell product candidates intended to address cancer, cardiac disease, and diabetes. CB001, its lead cord blood derived stem cell therapy product candidate, is being developed for hematopoietic stem cell transplantation in patients affected by a variety of cancers. In addition to its therapeutic development programs, ViaCell’s reproductive health business commercializes ViaCord®, a product that offers expecting families the option of preserving their baby’s umbilical cord blood. The Company is working to leverage its commercial infrastructure and product development capabilities by developing ViaCyteSM, its investigational product intended to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell is headquartered in Cambridge, Massachusetts with a processing and storage facility in Kentucky and additional research and development operations in Singapore. Additional information about ViaCell is available online at http://www.viacellinc.com.

    This press release contains forward-looking statements regarding the Company’s sibling donor cord blood program. Such statements are based on management's current beliefs and expectations. There are a number of risks and uncertainties that could cause actual results to differ materially from management’s current beliefs and expectations. Factors which could cause actual results to differ materially from the Company's current expectations include, but are not limited to: the impact of any potential adverse outcome in pending patent infringement litigation related to the cord blood preservation business, any other unexpected material issues, delays or failures in the collection, processing or storage of umbilical cord blood by the Company or CHORI, any unexpected technical hurdles or issues that may arise, and the impact of competition in the umbilical cord blood preservation industry. For more information on the risks and uncertainties associated with the Company and its products and programs, see the factors set forth under the heading “Risk Factors That May Affect Results” in the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2006, which is on file with the Securities and Exchange Commission and which factors are incorporated herein by reference. ViaCell does not undertake any obligation to update forward-looking statements.

     

    ViaCell® and ViaCord® are federally registered trademarks and ViaCyteSM is a service mark of ViaCell, Inc.

  20. First FDA Clearance of Sterile Field Cord Blood Collection Bag

    FOR IMMEDIATE RELEASE
    4/25/06

     



     

    East Hills, NY and Cambridge, MA (April 25, 2006) -- ViaCell, Inc. (NASDAQ: VIAC) and Pall Corporation (NYSE: PLL) announced today the first U.S. Food and Drug Administration clearance of a cord blood collection bag suitable for use in a sterile field. Pall and ViaCell collaborated on the development and design of the new collection bag. ViaCell has exclusive rights to the new collection bag for family cord blood banking and expects to introduce it as part of its ViaCord® collection kit. The new sterile field bag will give families and their health care providers the ability to more safely and easily collect umbilical cord blood from newborns, even when born by cesarean section.

     

    Umbilical cord blood is a valuable source of stem cells used to treat more than 40 life threatening diseases including a wide range of cancers, immune deficiencies and genetic disorders. Collection of cord blood is a critical first step in the process of preserving a baby's umbilical cord blood to meet these and other future medical needs. It is important that the collection kit simply and aseptically collect as much blood as possible since larger units for cord blood generally produce more viable stem cells.

     

    “I believe the new ViaCord collection bag provides a significant benefit to the obstetrician,” said Yoni Branhard, M.D., Vice Chairman of the OB-GYN Department, Lenox Hill Hospital, New York City. “This is an innovative initiative in cord blood banking. The sterile bag gives my colleagues and me the comfort that, no matter how we deliver a child – vaginally or by cesarean - we are collecting the cord blood in a high quality manner.”

     

    Collecting blood from the umbilical cord of babies born by cesarean section, unlike vaginal births, must be done in a sterile surgical field. There are about 1.2 million cesarean sections performed in the U.S. each year, representing about 30 percent of all births. Since not all cesarean births are planned, ViaCell intends to include the new sterile field bag in its ViaCord collection kit provided to all expectant families who decide to preserve their baby's umbilical cord blood. Expectant parents and medical professionals will then have the optimal tools to collect their infant's cord blood, no matter the type of birthing situation.

     

    Karen A. Foster, Vice President, ViaCord Processing Laboratory, said, "We are excited by our collaboration with Pall in developing this innovative bag that allows us to continue offering families the highest quality product. This is a significant development in cord blood collection and further demonstrates our commitment and ability to lead technological advancements in cord blood banking.”

     

    "Our agreement with ViaCell is another milestone in Pall's development and customization of tools to help make cell therapy routine, safe and simple," says Judy Angelbeck, PhD, Senior Vice President, Pall New Technologies. "We are proud to work with ViaCell as they are committed to the highest standards of cord blood collection, processing and storage for family cord blood banking."

     

    Pall products are used by many of the leading cord blood transplant centers in the U.S. and its collection sets were used in the landmark Cord Blood Transplantation (COBLT) study which defines the standards on the use of stem cells from umbilical cord blood.

     

    About Pall Corporation

    Pall Corporation is the global leader in the rapidly growing field of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, semiconductor, water purification, aerospace and broad industrial markets. Total revenues for fiscal 2005 were $1.9 billion. The Company headquarters are in East Hills, New York with extensive operations throughout the world. Visit Pall at www.pall.com.

     

    About ViaCell, Inc.

    ViaCell is a biotechnology company focused on enabling the widespread use of human cells as medicine. The Company is developing a pipeline of proprietary stem cell product candidates intended to address cancer, cardiac disease, and diabetes. CB001, its lead cord blood derived stem cell therapy product candidate, is being developed for hematopoietic stem cell transplantation in patients affected by a variety of cancers. In addition to its therapeutic development programs, ViaCell's Reproductive Health Business commercializes ViaCord®, a product that offers expecting families the option of preserving their baby's umbilical cord blood. The Company is working to leverage its commercial infrastructure and product development capabilities by developing ViaCyteSM, its investigational product intended to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell is headquartered in Cambridge, Massachusetts with a processing and storage facility in Kentucky and additional research and development operations in Singapore. Additional information about ViaCell is available online at http://www.viacellinc.com.

     

    This press release contains forward-looking statements regarding the planned introduction by ViaCell of a new sterile field collection bag and the potential advantages of such a bag. Such statements are based on management's current expectations. The introduction and market acceptance of a new collection bag is subject to a number of risks and uncertainties. Factors which could cause actual results to differ materially from the Company’s current expectations include, but are not limited to, unexpected delays or clinical or technical hurdles related to the use or supply of the new collection bag or unexpected data related to processing of cord blood using the bag. For more information on the risks and uncertainties associated with ViaCell and its products and programs, see the factors set forth under the heading "Risk Factors That May Affect Results" in the Company's report on Form 10-K for the year ending December 31, 2005, which is on file with the Securities and Exchange Commission. ViaCell does not undertake any obligation to update forward-looking statements.

     

    ViaCord® and ViaCell® are federally registered trademarks and ViaCyteSM is a service mark of ViaCell, Inc.

    # # #

    Editor’s Notes:

    · A photo of the new sterile field cord blood collection bag can be found on http://www.pall.com/corporate_39574.asp

    · Additional information about Pall Corporation’s capabilities that enable the promises of cell therapy and regenerative medicine can be found at http://www.pall.com/medical_38352.asp

    · Additional information about ViaCord can be found at http://www.viacord.com

  21. PerkinElmer's ViaCord® Cord Blood Banking Business Collaborates with Miracle Babies to Improve Collection of Stem Cells from Premature Births for Potential Therapeutic Use

    FOR IMMEDIATE RELEASE 
    December 21, 2011 
     

    PerkinElmer's ViaCord® Cord Blood Banking Business Collaborates with Miracle Babies to Improve Collection of Stem Cells from Premature Births for Potential Therapeutic Use

    Collaboration will investigate non-controversial source of potential stem cell therapies for premature babies
     
    WALTHAM, Mass.--(BUSINESS WIRE)-- PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, announced today that its family cord blood banking business, ViaCord®, entered into a collaborative study with Miracle Babies, a non-profit organization supporting families with newborns in Neonatal Intensive Care Units (NICU). 
     
    This collaboration will study and promote the discovery of methods for optimizing collection of umbilical cord blood and cord tissue stem cells following premature births, providing a valuable resource for potential therapeutic use. Participating families will benefit from complimentary collection of their baby's umbilical cord blood, which has been shown to treat nearly 80 life-threatening diseases, and cord tissue, a rich source of mesenchymal stem cells expected to play an important role in regenerative medicine.
     
    The study will focus on infants born prior to the 34th week of pregnancy and findings will provide insight into the unique characteristics of umbilical cord blood and tissue stem cells of babies born prematurely. Throughout the study, researchers will obtain data surrounding cord blood and cord tissue stem cell collection in premature infants, including volume, tissue mass, cellular composition and other variables. Collections for the study will be taken at Sharp Mary Birch Hospital for Women & Newborns in San Diego.
     
    "The therapeutic benefits of umbilical cord blood and cord tissue stem cells have the potential to address significant unmet need in the treatment of severe illnesses in premature babies," said Morey Kraus, Chief Scientific Officer, ViaCord. "By understanding the conditions surrounding stem cell collection and the characteristics of stem cells from premature babies, we hope to improve therapeutic options in this particular demographic where access to stem cell therapies has been historically challenging, yet have the potential to be especially beneficial."
     
    "Our collaboration with ViaCord aligns with our goal of holistically providing support for families with premature infants," said Sean Daneshmand, MD, founder of Miracle Babies. "This effort will have significant implications in improving treatment access for the one in eight babies born prematurely in the U.S. every year."
     
    Individuals born prematurely have shown to be more susceptible to a range of health complications, including intellectual disability, lung problems and vision and hearing loss. A recent study published in the Journal of the American Medical Association also found that babies born prematurely are at an especially increased risk for cerebral palsy1, an indication which is currently under investigation in FDA sanctioned clinical protocols using cord blood stem cells. Current research is determining the role of umbilical cord-derived stem cells in the treatment of a variety of other diseases with no known cure, such as Type 1 Diabetes and leukemia. This advancement of stem cell research and extraction in preterm births may improve the availability of future therapeutic options for individuals born prematurely.
     
    For more information about the study and collaboration between ViaCord and Miracle Babies, please visit www.miraclebabies.org.
     
    ViaCord's family cord blood banking services currently offers expectant families the opportunity to preserve their baby's umbilical cord blood and cord tissue for potential medical use by the child or a related family member. To date, ViaCord has preserved the umbilical cord blood of more than 250,000 newborns. Twenty years ago, cord blood stem cells were used to treat just one disease, Fanconi's anemia. Today there are nearly 80 diseases treatable with cord blood stem cells, including cancers, certain blood disorders and immunodeficiencies. Please visit www.viacord.com for more information.
     
    About Miracle Babies
     
    Our mission is to provide education, support, and financial assistance to families with newborns in the neonatal intensive care unit (NICU). Every year more than 500,000 babies are born prematurely. As overwhelmed families grapple with the terrifying uncertainties, they often find themselves faced with unexpected financial difficulties. With something so precious to lose, it is important that we give as much as we can. To learn more about how you can help Miracle Babies, please visit http://www.miraclebabies.org.
     
    About PerkinElmer, Inc.
     
    PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.7 billion in 2010, has about 7,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
     
    1 Moster, D., et. al. (2010). Cerebral Palsy Among Term and Postterm Births. Journal of the American Medical Association. 304 (9), 976 — 982.
     
     
     
    Edelman (On behalf of PerkinElmer, Inc.)
    Amanda L. Connolly, 404-832-6785
    Amanda.Connolly@edelman.com
     
    Source: PerkinElmer, Inc.
     
    News Provided by Acquire Media
  22. PerkinElmer's ViaCord® Cord Blood Banking Business to Expand Stem Cell Harvesting Capabilities

    WALTHAM, Mass.--(BUSINESS WIRE)-- PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, announced today that its family cord blood banking business, ViaCord®, will now offer families the ability to extract stem cells from the tissue surrounding the umbilical cord vessels, a very rich source of mesenchymal stem cells (MSCs). 

    This new capability is exclusive to ViaCord, the only cord blood banking service with patent rights to expand MSCs from cord tissue as well as extract and expand MSCs from the tissue around the cord vessels. This proprietary service will be offered, as part of the current cord tissue stem cell service offering, to expectant parents through an exclusive licensing agreement with Tissue Regeneration Therapeutics (TRT). 


    "The agreement between ViaCord and TRT provides our customers with access to a very rich source of MSCs from umbilical cord tissue, increasing their chances of potential success and benefit from possible therapeutic applications. In addition, the agreement will further distinguish ViaCord's portfolio of offerings in the area of cord tissue banking," said Morey Kraus, chief scientific officer for ViaCord. "ViaCord will also collaborate with TRT on a research initiative investigating the therapeutic benefits and anti-inflammatory properties of this rich source of MSCs. This research is intended to achieve results that may guide clinical studies of stem cell applications for joint diseases, including rheumatoid arthritis and osteoarthritis, as well as autoinflammatory diseases, such as irritable bowel syndrome." 

    "ViaCord has established a lead position in the study and identification of new uses for stem cell treatments within the clinical setting, and is an ideal complement to the robust scientific foundation that we, at TRT, have built in the MSC field," said John E. Davies, president and chief executive officer of Tissue Regeneration Therapeutics. "We are delighted that ViaCord customers will benefit from this exclusive licensing agreement and our collaborative research to advance therapeutic uses of MSCs." 

    The extraction is enabled through TRT's human umbilical cord perivascular cell (HUCPVC) technology, allowing ViaCord to extract the stem cells found around the umbilical cord vessels. This process creates access to perivascular MSCs, a highly potent type of stem cell, which offers a potentially significant medical advantage. ViaCord's added ability to expand the stem cells can also increase the available supply by tenfold or greater, providing more stem cells for more potential treatments. Banking newborn cord tissue stem cells in addition to cord blood stem cells provides a greater number and variety of cells, increasing chances of potential success and benefit from possible therapeutic applications. 

    The partnership with TRT augments the proprietary position that was initiated by the agreement between ViaCord and AuxoCell Laboratories, Inc., which was entered into in March 2011. The combined agreements provide ViaCord customers with exclusive access to both MSC extraction and expansion technologies. 

    ViaCord family cord blood banking services currently offers expectant families the opportunity to preserve their baby's umbilical cord blood for potential medical use by the child or a related family member. To date, ViaCord has preserved the umbilical cord blood of more than 250,000 newborns. Twenty years ago, cord blood stem cells were used to treat just one disease, Fanconi's anemia. Today there are nearly 80 diseases treatable with cord blood stem cells, including cancers, certain blood disorders and immunodeficiencies. 

    About Tissue Regeneration Therapeutics (TRT) 

    TRT is a progressive biotechnology Canadian Controlled Private Corporation (CCPC) with a focus on the commercial development of their patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology, which represents the world's richest source of mesenchymal stem cells (MSCs). TRT is the first company in the world to have issued and allowed patents in both the USA and Europe for extraction of these unique cells from umbilical cord tissue. TRT provides license opportunities to collaborating partner companies in the regenerative therapeutics industry, including Family Banking. In June 2006, TRT exclusively licensed rights for the Canadian market to CReATe Cord Blood Bank in Toronto, who market HUCPVCs as PeristemTM, making both TRT and CreATe leaders in the worldwide stem cell community. TRT's preclinical and clinical development programs are designed to develop therapies that address important health care issues of today. Additional information is available at www.verypowerfulbiology.com. 

    About PerkinElmer, Inc. 

    PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.7 billion in 2010, has about 6,200 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. 

    Additional information is available through 1-877-PKINYSE, or at www.perkinelmer.com. Edelman (On behalf of PerkinElmer, Inc.) 
    Amanda L. Connolly, 404-832-6785
    amanda.connolly@edelman.com

    Source: PerkinElmer, Inc. News Provided by Acquire Media

  23. PerkinElmer’s ViaCord® Family Cord Blood Banking Business Announces First and Only Service to Bank Stem Cells Harvested from Umbilical Cord Tissue

    PerkinElmer’s ViaCord® Family Cord Blood Banking Business Announces First and Only Service to Bank Stem Cells Harvested from Umbilical Cord Tissue Addition of cord tissue stem cell banking services expands patient access to potential therapeutic benefit through more volume and variety of stem cells

    WALTHAM, MA – PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced that its family cord blood banking business, ViaCord®, will now offer expectant parents umbilical cord tissue stem cell banking services. This latest addition to the ViaCord portfolio complements its cord blood banking service. Umbilical cord tissue is a rich source of mesenchymal stem cells (MSCs). Banking newborn cord tissue stem cells in addition to cord blood stem cells provides a greater number and variety of cells, so patients may increase their chances of potential success and benefit from possible therapeutic applications. Results from more than 50 preclinical studies involving MSCs extracted from cord tissue have been published, underscoring the potential treatment value of MSCs to the scientific and medical community. Published research has found that tissue-derived stem cells have been shown to offer potential treatment of disorders such as Parkinson’s, stroke, type1 diabetes and sports injuries. The new services are enabled through an exclusive licensing agreement with AuxoCell Laboratories, Inc., a leading stem cell therapeutic and regenerative medicine company. Under the terms of the license agreement, ViaCord’s customers are granted exclusive family banking access to Auxocell’s patent for expanding MSCs derived from umbilical cord tissue. Additionally, ViaCord uses Auxocell’s validated technology for processing and cryopreserving MSCs from umbilical cord tissue. "Researchers in a preclinical study, presented by AuxoCell, at the October 2010 meeting of the International Placenta Stem Cell Society, found that combining the stem cells from umbilical cord tissue with stem cells from cord blood results in improved engraftment – up to a six-times increase over cord blood alone," said Morey Kraus, ViaCord’s chief scientific officer. "ViaCord is excited to offer another source of stem cells to our customers. In addition, our relationship with Auxocell allows us to provide our family banking customers with even greater confidence through deploying a validated method for processing these cells and exclusive access to expanding these cells." ViaCord family cord blood banking services currently offers expectant families the opportunity to preserve their baby’s umbilical cord blood for potential medical use by the child or a related family member. To date, ViaCord has preserved the umbilical cord blood of more than 250,000 newborns. Twenty years ago, cord blood stem cells were used to treat just one disease, Fanconi’s anemia. Today there are nearly 80 diseases treatable with cord blood stem cells, including cancers, certain blood disorders and immunodeficiencies. About PerkinElmer, Inc. PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.7 billion in 2010, has about 6,200 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com. # # # Media Contact: Amanda L. Connolly Edelman (On behalf of PerkinElmer, Inc.) Phone: (404) 832-6785 Email: amanda.connolly@edelman.com

  24. PerkinElmer Commences Cash Tender Offer for ViaCell

    FOR IMMEDIATE RELEASE

    10/12/07


     

    WALTHAM and CAMBRIDGE, Mass. (October 12, 2007) – On October 12, 2007, Victor Acquisition Corp., an indirect wholly owned subsidiary of PerkinElmer, Inc. (NYSE: PKI), commenced a tender offer to acquire all outstanding shares of common stock of ViaCell, Inc. (Nasdaq: VIAC), at a price of $7.25 per share, in cash, pursuant to a previously announced Agreement and Plan of Merger among PerkinElmer, Inc., Victor Acquisition Corp. and ViaCell, Inc., dated October 1, 2007.

     

    Victor Acquisition Corp.’s obligation to accept for payment and pay for shares of ViaCell common stock tendered in the offer is subject to customary conditions, including, among other things:at least a majority of the outstanding shares of ViaCell common stock on a fully diluted basis shall have been validly tendered in accordance with the terms of the offer and not properly withdrawn; and,

    the expiration or termination of applicable waiting periods under the United States Hart-Scott-Rodino Antitrust Improvements Act. The tender offer and any withdrawal rights to which ViaCell’s stockholders may be entitled will expire at 12:00 midnight, New York City time, at the end of November 8, 2007, unless the offer is extended.

     

    The complete terms and conditions of the tender offer are set forth in the Offer to Purchase, Letter of Transmittal and other related materials filed by PerkinElmer with the SEC on October 12, 2007. ViaCell filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC on October 12, 2007, relating to the tender offer. Copies of the Offer to Purchase, Letter of Transmittal and other related materials are available free of charge from Georgeson, Inc., the Information Agent for the tender offer, toll-free at (888) 821-2250 (banks and brokers at (212) 440-9800), or Merrill Lynch & Co., the Dealer Manager for the tender offer, at (877) 653-2948, toll-free. Deutsche Bank Trust Company Americas is acting as Depositary for the tender offer.

     

    Securities Law Disclosure

     

    This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any securities. The solicitation and the offer to buy shares of ViaCell common stock are being made only pursuant to the Offer to Purchase, Letter of Transmittal and related materials that PerkinElmer, Inc. and Victor Acquisition Corp. have filed with the SEC on a Tender Offer Statement on Schedule TO on October 12, 2007. ViaCell also has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer on October 12, 2007. ViaCell stockholders and other investors should read these materials carefully because they contain important information, including the terms and conditions of the offer. ViaCell stockholders and other investors may obtain copies of these materials without charge from the SEC through the SEC’s Web site at www.sec.gov, from Georgeson, Inc., the information agent for the offer, toll-free at (888) 821-2250 (banks and brokers at (212) 440-9800), from Merrill Lynch & Co., the Dealer Manager for the tender offer, at (877) 653-2948, toll-free, from PerkinElmer by directing a request to PerkinElmer, 940 Winter Street, Waltham, Massachusetts 02451, Attention: Michael A. Lawless, Vice President, Investor Relations or from ViaCell, Inc., 245 First Street, Cambridge, Massachusetts, 02142, Attention: Justine Koenigsberg, Senior Director, Corporate Communications. Stockholders and other investors are urged to read carefully those materials prior to making any decisions with respect to the offer.

     

    Cautionary Note Regarding Forward-Looking Statements

     

    Statements in this press release regarding the proposed transaction between PerkinElmer and ViaCell, the expected timetable for completing the proposed transaction, and any other statements about PerkinElmer or ViaCell managements’ future expectations, beliefs, goals, plans or prospects constitute forward-looking statements. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the possibility that certain closing conditions to the transaction will not be met, the ability to consummate the transaction, the ability of PerkinElmer to successfully integrate ViaCell’s operations and employees; the ability to realize anticipated synergies and cost savings; and the other factors described in PerkinElmer’s Annual Report on Form 10-K for the year ended December 31, 2006, and in ViaCell’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, each of which has been filed with the SEC. Except as otherwise required by law, PerkinElmer and ViaCell disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

     

    About PerkinElmer

     

    PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. PerkinElmer, Inc. reported revenues of $1.55 billion in 2006, has 8,500 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

     

    About ViaCell

     

    ViaCell, Inc. is a biotechnology company dedicated to enabling the widespread application of human cells as medicine. ViaCell markets ViaCord, a product offering through which families can preserve their baby’s umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases. ViaCell is also working to leverage its commercial infrastructure and product development capabilities by developing ViaCyteSM, a product candidate being studied for its potential to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell also conducts research and development primarily to investigate other potential therapeutic uses of umbilical cord blood-derived stem cells and on technology for expanding populations of these cells. ViaCell's pipeline is focused in the areas of cancer, cardiac disease, and diabetes. Additional information about ViaCell is available online at http://www.viacellinc.com. Additional information about ViaCord is also available at http://www.viacord.com.

     

    # # #

     

    For further information:

     

    PerkinElmer Investor Contact: PerkinElmer Media Contact:

     

    Michael A. Lawless Kevin J. Lorenc

     

    (781) 663-5659 (781) 663-5701

     

     

     

    PerkinElmer, Inc.

    940 Winter Street

    Waltham, MA 02451 USA

    Phone: 781-663-6900

    Fax: 781-663-5985

    www.perkinelmer.com

  25. ViaCord Releases 250th Cord Blood Stem Cell Unit

    FOR IMMEDIATE RELEASE
    March 26, 2013

     
     

    ViaCord Releases 250th Cord Blood Stem Cell Unit
    PerkinElmer's Family Cord Blood and Tissue Preservation Business Reaches Significant Milestone


    ViaCord, PerkinElmer's family cord blood and tissue preservation business, announced today the release of its 250th umbilical cord blood stem cell unit for use in medical treatments and clinical trials. For nearly 20 years, ViaCord has released life-saving stem cells for disease therapies using a proven method of processing and cryopreserving cord blood. To date, ViaCord has released more units for use in medical treatments and clinical trials than any other family bank.

    "Reaching this milestone is a testament to our dedication to improving the quality of life for families," said Morey Kraus, Chief Scientific Officer, ViaCord. "The benefits of cord blood banking are constantly evolving as research, some of which ViaCord has been instrumental in supporting, continues to expand the number of diseases treated. We are excited to continue to assist families who have chosen to bank their newborns' stem cells."

    Cord blood stem cells have been used in the treatment of nearly 80 diseases, and more than 30,000 treatments have been conducted worldwide using cord blood stem cells. ViaCord has released stem cells for the treatment of diseases ranging from acute lymphoblastic leukemia, thalassemia major and sickle cell disease. ViaCord's 250th unit was used to treat a patient currently enrolled in the Duke Translational Medicine Institute's Cerebral Palsy Autologous Cord Blood clinical trial conducted at Duke University Medical Center. In this clinical trial, researchers are investigating the potential benefits of autologous reinfusion of cord blood stem cells for children with cerebral palsy.

    ViaCord has preserved the umbilical cord stem cells of more than 300,000 newborns. ViaCord's family cord blood and cord tissue services currently offer expectant families the opportunity to bank their baby's umbilical cord blood and tissue for potential medical use by the child or a related family member. Through its Sibling Connection Program, ViaCord also provides the opportunity for expectant parents, who have an eligible child in need of a transplant, to receive cord blood and cord tissue stem collection, processing and five years of storage, at no cost. Please visit www.viacord.com for more information.

    About PerkinElmer, Inc.
    PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $2.1 billion in 2012, has about 7,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

    # # #

    Media Contact:
    Jen Reid Edelman (On behalf of PerkinElmer, Inc.)
    Phone: (404) 460-8587
    Email: jen.reid@edelman.com

  26. ViaCell Reports Encouraging Preclinical Findings of Unrestricted Somatic Stem Cells from Cord Blood

    FOR IMMEDIATE RELEASE

    3/16/06

     

    Atlanta, GA, March 13, 2006  ViaCell, Inc. (Nasdaq: VIAC) announced today preclinical findings evaluating Unrestricted Somatic Stem Cells (USSCs), pluripotent stem cells cultivated from human cord blood, in a small animal model of myocardial infarction. In the study USSCs showed a dose-dependent response and result in functional recovery in an animal model of acute myocardial infarction four weeks post transplantation. These findings were presented today by Dr. Hiroto Iwasaki of Kobe Institute of Biomedical Research and Innovation/RIKEN Center for Developmental Biology in Isehara, Japan at the American College of Cardiology 55th Annual Scientific Session being held in Atlanta, Georgia.

     

    “These data are very exciting as we’ve seen few examples of a dose-dependent effect of stem cells demonstrated in the cardiac field thus far. While further research is needed, we also demonstrated USSCs differentiate into both endothelial and cardiomyocytes,” said Dr. Takayuki Asahara of Kobe Institute of Biomedical Research and Innovation/RIKEN Center for Developmental Biology. “Through our work with ViaCell evaluating their proprietary USSCs, we are encouraged about the potential these cells may have to regenerate damaged heart tissue.”

     

    The primary goal of this study was to determine if USSCs would lead to functional improvement after acute myocardial infarction in a small animal model. USSCs were implanted 20 minutes after an acute myocardial infarction was induced by ligating one of the coronary arteries. Key research findings showed engraftment of USSCs in the infarct region and a dose-dependent improvement of heart function conferred by USSCs whereby human skin fibroblasts did not induce any improvement.

     

    “We are encouraged with these research findings and intend to advance this program further in preclinical testing to determine optimal dosing, delivery, and targeting of USSCs as a treatment for cardiac disease. With over 800,000 annual cases of patients surviving a myocardial infarction and 5 million people suffering from chronic heart failure and no proven therapy to repair or regenerate the heart, we believe our USSC program is an important initiative,” said Stephan Wnendt, Ph.D., Senior Vice President of Research and Development at ViaCell.

     

    If the preclinical data support further development, ViaCell expects to file an Investigational New Drug Application (IND) to commence human clinical trials of its USSCs in the cardiac area in late 2006 or early 2007.

     

    Unrestricted somatic stem cells are a pluripotent source of stem cells cultivated from human cord blood mononuclear cells. These cells have the ability to differentiate into many cell types including endothelial cells, fat, bone, cartilage and neuronal cells under specified in vitro culture conditions. Preclinical evidence suggests USSCs can differentiate in vivo in many tissue types as shown by distribution and function of human cells in the liver, bone, bone marrow, brain and heart of transplanted animals. The company believes USSCs may have potential in a number of indications.

     

    Acute myocardial infarction (AMI), or heart attack, occurs when the blood supply to part of the heart muscle is severely reduced or stopped. This occurs when one of the heart's arteries is blocked by an obstruction, such as a blood clot that has formed or plaque formed by arteriosclerosis. If the blood supply is cut off drastically or for a long time, heart muscle cells suffer irreversible injury and die. According to a study by the National Heart, Lung and Blood Institute, there are approximately 1.2 million cases of myocardial infarction each year in the United States, with a fatal outcome in about 42% of cases. Many patients who survive develop a chronic form of heart disease called congestive heart failure (CHF) which is associated with a progressive deterioration of the heart muscle. According to the National Heart, Lung and Blood Institute, approximately 5 million patients suffer from CHF in the United States.

     

    About ViaCell ViaCell is a biotechnology company focused on enabling the widespread use of human cells as medicine. The Company is developing a pipeline of proprietary stem cell product candidates intended to address cancer, cardiac disease, and diabetes. CB001, its lead cord blood derived stem cell therapy product candidate, is being developed for hematopoietic stem cell transplantation in patients affected by a variety of cancers. In addition to its therapeutic development programs, ViaCell’s Reproductive Health Business Unit commercializes ViaCord®, a product that offers expecting families the option of preserving their baby’s umbilical cord blood. The Company is working to leverage its commercial infrastructure and product development capabilities by developing ViaCyteSM, its investigational product intended to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell is headquartered in Cambridge, Massachusetts with a processing and storage facility in Kentucky and additional research and development operations in Singapore.

     

    This press release contains forward-looking statements regarding the Company’s plans for development of its USSC product candidate, including the timing as to a possible IND filing, and the Company’s views as to the potential for USSCs in the cardiac area and in other indications. Such statements are based on management's current beliefs and expectations. Drug development involves a high degree of risk. There are a number of risks and uncertainties that could cause actual results to differ materially from management’s current beliefs and expectations. The Company’s USSC product candidate is at an early stage of development and has not completed preclinical testing or been tested in humans. Promising results in small animal studies may not be indicative of results that may be obtained in larger animal studies or in humans. Preclinical studies have yielded and may continue in the future to yield inconsistent results. We may not be able to find a way to successfully deliver and target cells to the damaged regions of the heart for trans-vascular delivery or other commercially viable route of administration. There is no assurance that we will be able to show effect in further animal models or that data will support filing the IND and starting clinical trials. Even if we are able to begin clinical trials, there is no assurance that we will be able to show that USSCs are safe and effective in the treatment of cardiac disease. We may encounter technical, regulatory, safety, manufacturing, delivery or intellectual property-related hurdles or issues as we develop this product candidate. For more information on the risks and uncertainties associated with the Company and its products and programs, see the factors set forth under the heading “Risk Factors That May Affect Results” in the Company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2005, which is on file with the Securities and Exchange Commission and which factors are incorporated herein by reference. ViaCell does not undertake any obligation to update forward-looking statements.

    ViaCell® and ViaCord® are registered trademarks and ViaCyteSM is a service mark of ViaCell, Inc.

     

    ViaCell�sc<sM �H --EndFragment--> ll�zcmsM �H :p>

     

    ViaCell® and ViaCord® are federally registered trademarks of ViaCell, Inc.

     

    ###